Bullfrog AI Holdings, Inc. Common Stock (BFRG) S-1 29 Jan 24 IPO registration Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2023
Entity Addresses [Line Items]
Document Type	S-1
Amendment Flag	false
Entity Registrant Name	BULLFROG AI HOLDINGS, INC.
Entity Central Index Key	0001829247
Entity Tax Identification Number	84-4786155
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	325 Ellington Blvd.
Entity Address, Address Line Two	Unit 317
Entity Address, City or Town	Gaithersburg
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20878
City Area Code	(240)
Local Phone Number	658-6710
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	325
Entity Address, Address Line Two	Unit 317
Entity Address, City or Town	Gaithersburg
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20878
City Area Code	(240)
Local Phone Number	658-6710
Contact Personnel Name	Vininder Singh

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 3,856,037	$ 57,670	$ 10,014
Prepaid expenses	352,433	15,000
Total current assets	4,208,470	72,670	10,014
NON-CURRENT ASSETS:
Property and equipment, net	6,406	7,699
Total Non-Current Assets		7,699
Total assets	4,214,876	80,369	10,014
Current liabilities:
Accounts payable	110,503	543,993	68,594
Accrued expenses	122,257	982,988
Deferred revenue		32,000	10,000
Short term insurance financing	213,290
Notes payable-related party			49,000
Convertible notes		1,323,890	284,038
Convertible notes - related party		254,850	253,266
Total current liabilities	446,050	3,137,721	1,019,121
TOTAL LIABILITIES		3,137,721	1,019,121
Stockholders’ deficit:
Series A Convertible Preferred stock, $0.00001 par value, 5,500,000 shares authorized; 73,449 shares issued and outstanding, as of September 30, 2023 and December 31, 2022.	1	1
Common stock, $0.00001 par value, 100,000,000 shares authorized; 6,094,644 and 4,021,935 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively.	61	40	46
Additional paid-in capital	12,226,742	1,341,662	587,415
Accumulated deficit	(8,457,978)	(4,399,055)	(1,596,568)
Total stockholders’ deficit	3,768,826	(3,057,352)	(1,009,107)
Total liabilities and stockholders’ deficit	$ 4,214,876	80,369	10,014
Nonrelated Party [Member]
Current liabilities:
Accrued expenses		416,072	68,557
Related Party [Member]
Current liabilities:
Accrued expenses		566,916	285,666
Notes payable-related party			$ 49,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Debt discount		$ 0	$ 12,962
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued			0
Common stock, par value	$ 0.00001	$ 0.00001	$ 0.00001
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, shares, issued	6,094,644	4,021,935	4,622,789
Common stock, shares, outstanding	6,094,644	4,021,935	4,622,789
Series A Preferred Stock [Member]
Preferred stock, par value		$ 0.00001	$ 0.00001
Preferred stock, shares authorized		5,500,000	5,500,000
Preferred stock, shares issued		73,449	0
Preferred stock, shares outstanding		73,449	0
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	5,500,000	5,500,000
Preferred stock, shares issued	73,449	73,449
Preferred stock, shares outstanding	73,449	73,449
Related Party [Member]
Debt discount		$ 0	$ 1,584

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Revenue, net	$ 65,000		$ 65,000		$ 10,000
Total revenue	65,000		65,000		10,000
Cost of goods sold:
Cost of goods sold	5,200		5,200		800
Total cost of goods sold	5,200		5,200		800
Gross profit	59,800		59,800		9,200
Operating expenses:
Research and development	380,015	39,421	1,023,619	448,375	609,270	25,000
General and administrative	983,929	601,131	3,067,940	1,424,383	1,307,882	327,329
Payroll and salary					98,250
Payroll and salary-related party					449,599	203,033
Total operating expenses	1,363,944	640,552	4,091,559	1,872,758	2,465,001	555,362
Loss from operations	(1,304,144)	(640,552)	(4,031,759)	(1,872,758)	(2,455,801)	(555,362)
Other income (expense), net
Interest expense, net	(5,758)	(124,159)	(76,880)	(234,668)	(347,145)	(40,395)
Loss on conversion of notes			(92,959)
Other (expense) income, net	56,924	18	142,675	457	459	9,917
Total other income (expense), net	51,166	(124,141)	(27,164)	(234,211)	(346,686)	(30,478)
Net loss	$ (1,252,978)	$ (764,693)	$ (4,058,923)	$ (2,106,969)	$ (2,802,487)	$ (585,840)
NET (LOSS) PER COMMON SHARE:
Net loss per common share attributable to common stockholders basic	$ (0.21)	$ (0.16)	$ (0.72)	$ (0.45)	$ (0.70)	$ (14)
Net loss per common share attributable to common stockholders diluted	$ (0.21)	$ (0.16)	$ (0.72)	$ (0.45)	$ (0.70)	$ (14)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:
Weighted average number of shares outstanding - basic	6,094,644	4,752,959	5,667,997	4,669,952	4,009,852	4,116,336
Weighted average number of shares outstanding - diluted	6,094,644	4,752,959	5,667,997	4,669,952	4,009,852	4,116,336

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Receivables from Stockholder [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2020		$ 36	$ 470,274	$ (100)	$ (1,010,728)	$ (540,518)
Balance, shares at Dec. 31, 2020		3,603,422
Cash from subscription receivables				100		100
Warrants issued with convertible notes			13,661			13,661
Imputed interest			4,539			4,539
Stock-based compensation			9,385			9,385
Equity compensation		$ 10	89,556			89,566
Equity compensation, shares		1,019,367
Net loss					(585,840)	$ (585,840)
Issuance of common stock for services, shares						29,286
Balance at Dec. 31, 2021		$ 46	587,415		(1,596,568)	$ (1,009,107)
Balance, shares at Dec. 31, 2021		4,622,789
Imputed interest			2,360			2,360
Stock-based compensation			30,017			30,017
Net loss					(566,359)	(566,359)
Reclassification of warrant			(11,097)			(11,097)
Balance at Mar. 31, 2022		$ 46	608,695		(2,162,927)	(1,554,186)
Balance, shares at Mar. 31, 2022		4,622,789
Balance at Dec. 31, 2021		$ 46	587,415		(1,596,568)	(1,009,107)
Balance, shares at Dec. 31, 2021		4,622,789
Net loss						(2,106,969)
Balance at Sep. 30, 2022		$ 47	1,290,130		(3,703,537)	(2,413,360)
Balance, shares at Sep. 30, 2022		4,756,427
Balance at Dec. 31, 2021		$ 46	587,415		(1,596,568)	(1,009,107)
Balance, shares at Dec. 31, 2021		4,622,789
Imputed interest			9,221			9,221
Stock-based compensation			340,152			340,152
Net loss					(2,802,487)	(2,802,487)
Conversion of convertible notes		$ 2	226,136			226,138
Conversion of convertible notes, shares		205,984
Reclassification of warrant			(11,097)			(11,097)
Shares cancellation		$ (1)	1
Shares cancellation, shares		(112,225)
Issuance of common stock pursuant to warrant exercises			189,828			189,828
Issuance of common stock pursuant to warrant exercises, shares		39,879
Common stocks converted to Series A Preferred stock	$ 1	$ (7)	6
Common stocks converted to Series A Preferred stock, shares	73,449	(734,492)
Balance at Dec. 31, 2022	$ 1	$ 40	1,341,662		(4,399,055)	(3,057,352)
Balance, shares at Dec. 31, 2022	73,449	4,021,935
Balance at Mar. 31, 2022		$ 46	608,695		(2,162,927)	(1,554,186)
Balance, shares at Mar. 31, 2022		4,622,789
Imputed interest			2,361			2,361
Stock-based compensation			209,323			209,323
Net loss					(775,917)	(775,917)
Conversion of convertible notes		$ 2	226,136			226,138
Conversion of convertible notes, shares		205,984
Shares cancellation		$ (1)	1
Shares cancellation, shares		(112,225)
Balance at Jun. 30, 2022		$ 47	1,046,516		(2,938,844)	(1,892,281)
Balance, shares at Jun. 30, 2022		4,716,548
Imputed interest			2,250			2,250
Stock-based compensation			51,536			51,536
Net loss					(764,693)	(764,693)
Shares issuance for license			189,828			189,828
Shares issuance for license, shares		39,879
Balance at Sep. 30, 2022		$ 47	1,290,130		(3,703,537)	(2,413,360)
Balance, shares at Sep. 30, 2022		4,756,427
Balance at Dec. 31, 2022	$ 1	$ 40	1,341,662		(4,399,055)	(3,057,352)
Balance, shares at Dec. 31, 2022	73,449	4,021,935
Stock-based compensation			127,450			127,450
Net loss					(1,325,547)	(1,325,547)
Conversion of convertible notes		$ 3	1,535,612			1,535,615
Conversion of convertible notes, shares		331,166
Issuance of common stock (initial public offering), net of issuance cots		$ 13	7,293,638			7,293,651
Issuance of common stock (initial public offering), net of issuance cots, shares		1,297,318
Issuance of common stock for services		$ 1	49,999			50,000
Issuance of common stock for services, shares		7,692
Balance at Mar. 31, 2023	$ 1	$ 57	10,348,361		(5,724,602)	4,623,817
Balance, shares at Mar. 31, 2023	73,449	5,658,111
Balance at Dec. 31, 2022	$ 1	$ 40	1,341,662		(4,399,055)	(3,057,352)
Balance, shares at Dec. 31, 2022	73,449	4,021,935
Net loss						(4,058,923)
Balance at Sep. 30, 2023	$ 1	$ 61	12,226,742		(8,457,978)	3,768,826
Balance, shares at Sep. 30, 2023	73,449	6,094,644
Balance at Mar. 31, 2023	$ 1	$ 57	10,348,361		(5,724,602)	4,623,817
Balance, shares at Mar. 31, 2023	73,449	5,658,111
Stock-based compensation			262,267			262,267
Net loss					(1,480,398)	(1,480,398)
Issuance of common stock pursuant to warrant exercises		$ 4	1,494,654			$ 1,494,658
Issuance of common stock pursuant to warrant exercises, shares		436,533
Issuance of common stock for services, shares						436,533
Balance at Jun. 30, 2023	$ 1	$ 61	12,105,282		(7,205,000)	$ 4,900,344
Balance, shares at Jun. 30, 2023	73,449	6,094,644
Stock-based compensation			121,460			121,460
Net loss					(1,252,978)	(1,252,978)
Balance at Sep. 30, 2023	$ 1	$ 61	$ 12,226,742		$ (8,457,978)	$ 3,768,826
Balance, shares at Sep. 30, 2023	73,449	6,094,644

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (4,058,923)	$ (2,106,969)	$ (2,802,487)	$ (585,840)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on conversion of notes	92,959			(9,917)
Depreciation	1,293	604	1,045
Shares issued for license		189,828	189,828
Shares issued for services	50,000
Stock-based compensation	511,177	290,876	340,152	98,951
Amortization of debt discount	20,000	174,998	214,429	12,665
Imputed interest		6,971	9,221	4,539
Changes in operating assets and liabilities:
Prepaid expense	(337,433)	(15,000)	(15,000)
Accounts payable	(433,490)	51,946	475,399	(25,853)
Accrued expenses	(796,865)	409,502	373,273	27,384
Accrued expenses - related party		104,000	281,250	85,666
Deferred revenue	(32,000)	22,000	22,000	10,000
Net cash used in operating activities	(4,983,282)	(871,244)	(910,890)	(382,405)
Cash flows from investing activities:
Purchases of property and equipment		(8,744)	(8,744)
Net cash used in investing activities		(8,744)	(8,744)
Cash flows from financing activities:
Proceeds from issuance of common stock (initial public offering), net of issuance costs	7,293,651
Proceeds from exercise of warrants	1,494,658
Proceeds from convertible notes payable		961,190	1,016,290
Proceeds from convertible notes payables-related party				298,900
Proceeds from notes payable	100,000
Payments of notes payable	(319,950)
Repayment of note payable and interest - related party		(49,000)	(49,000)
Proceeds from notes payables - related party				88,400
Proceeds net of payments short term insurance financing	213,290
Proceeds from subscription payable				100
Net cash provided by financing activities	8,781,649	912,190	967,290	387,400
Net increase in cash and cash equivalents	3,798,367	32,202	47,656	4,995
Cash and cash equivalents, beginning of period	57,670	10,014	10,014	5,019
Cash and cash equivalents, end of period	3,856,037	42,216	57,670	10,014
Supplemental cash flow information:
Cash paid for interest	93,916	4,399	5,757
Cash paid for taxes
Supplemental non-cash activity
Reclassification of warrant		11,097	11,097
Issuance of common stock upon conversion of notes payable	1,535,615
Conversion of convertible note payable		$ 226,138	226,138
Cancellation of common stocks			8
Shares issued for license			189,828
Shares issued for services			340,152	20
Warrants issued with convertible notes				$ 13,661

Organization and Nature of Busi

Organization and Nature of Business	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Business	1. Organization and Nature of Business Description of the Business Bullfrog AI Holdings, Inc. (“we”, “our” or the “Company”) was incorporated in the State of Nevada on February 6, 2020. Bullfrog AI Holdings, Inc. is the parent company of Bullfrog AI, Inc. and Bullfrog AI Management, LLC. which were incorporated in Delaware and Maryland, in 2017 and 2021, respectively. All of our operations are currently conducted through Bullfrog AI Holdings, Inc., which began operations on February 6, 2020. We are a company focused specifically on advanced AI/ML-driven analysis of complex data sets in medicine and healthcare. Our objective is to utilize our platform for precision medicine approach to drug asset enablement through external partnerships and selective internal development. Most new therapeutics will fail at some point in preclinical or clinical development. This is the primary driver of the high cost of developing new therapeutics. A major part of the difficulty in developing new therapeutics is efficient integration of complex and highly dimensional data generated at each stage of development to de-risk subsequent stages of the development process. Artificial Intelligence and Machine Learning (AI/ML) has emerged as a digital solution to help address this problem. We use artificial intelligence and machine learning to advance medicines for both internal and external projects. Most current AI/ML platforms still fall short in their ability to synthesize disparate, high-dimensional data for actionable insight. Our platform technology, named, bfLEAP™ is an analytical AI/ML platform developed at The Johns Hopkins University Applied Physics Laboratory (JHU-APL) which is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise, multi-dimensional understanding of their data. We are deploying bfLEAP™ for use at several critical stages of development for internal programs and through strategic partnerships and collaborations with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need. The bfLEAP™ platform utilizes both supervised and unsupervised machine learning – as such, it is able to reveal real/meaningful connections in the data without the need for a priori hypothesis. Algorithms used in the bfLEAP™ platform are designed to handle highly imbalanced data sets to successfully identify combinations of factors that are associated with outcomes of interest. Our primary goal is to improve the odds of success at any stage of pre-clinical and clinical therapeutics development, for in-house programs, and our strategic partners and collaborators. Our primary business model is enabling the success of ongoing clinical trials or rescue of late stage failed drugs (i.e., Phase 2 or Phase 3 clinical trial failures) for development and divestiture; although, we will also consider collaborations for earlier stage drugs. We hope to accomplish this through strategic acquisitions of current clinical stage and failed drugs for in-house development, or through strategic partnerships with biopharmaceutical industry companies. We are able to pursue our drug asset enhancement business by leveraging a powerful and proven AI/ML platform (trade name: bfLEAP™) initially developed at JHU-APL. We believe the bfLEAP™ analytics platform is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings. Liquidity and Going Concern The Company has had negative cash flows from operations and operated at a net loss since inception. In the first quarter of 2023, we completed our initial public offering (“IPO”). We believe that the funds raised and notes that were converted from debt to equity in connection with the IPO now provide enough liquidity to fund operations beyond 9 months from the date of this filing.	NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS Organization and Nature of Business Bullfrog AI Holdings, Inc. was incorporated in the State of Nevada on February 6, 2020. Bullfrog AI Holdings, Inc. is the parent company of Bullfrog AI, Inc. and Bullfrog AI Management, LLC. which were incorporated in Delaware and Maryland, in 2017 and 2021, respectively. All of our operations are currently conducted through BullFrog AI Holdings, Inc., which began operations on February 6, 2020. We are a company focused specifically on advanced AI/ML-driven analysis of complex data sets in medicine and healthcare. Our objective is to utilize our platform for precision medicine approach to drug asset enablement through external partnerships and selective internal development. Most new therapeutics will fail at some point in preclinical or clinical development. This is the primary driver of the high cost of developing new therapeutics. A major part of the difficulty in developing new therapeutics is efficient integration of complex and highly dimensional data generated at each stage of development to de-risk subsequent stages of the development process. Artificial Intelligence and Machine Learning (AI/ML) has emerged as a digital solution to help address this problem. We use artificial intelligence and machine learning to advance medicines for both internal and external projects. Most current AI/ML platforms still fall short in their ability to synthesize disparate, high-dimensional data for actionable insight. Our platform technology, named, bfLEAP™ is an analytical AI/ML platform developed at The Johns Hopkins University Applied Physics Laboratory (JHU-APL) which is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise, multi-dimensional understanding of their data. We are deploying bfLEAP™ for use at several critical stages of development for internal programs and through strategic partnerships and collaborations with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need. The bfLEAP™ platform utilizes both supervised and unsupervised machine learning – as such, it is able to reveal real/meaningful connections in the data without the need for an a priori hypothesis. Algorithms used in the bfLEAP™ platform are designed to handle highly imbalanced data sets to successfully identify combinations of factors that are associated with outcomes of interest. Our primary goal is to improve the odds of success at any stage of pre-clinical and clinical therapeutics development, for in house programs, and our strategic partners and collaborators. Our primary business model is enabling the success of ongoing clinical trials or rescue of late stage failed drugs (i.e., Phase 2 or Phase 3 clinical trial failures) for development and divestiture; although, we will also consider collaborations for earlier stage drugs. We hope to accomplish this through strategic acquisitions of current clinical stage and failed drugs for in-house development, or through strategic partnerships with biopharmaceutical industry companies. We are able to pursue our drug asset enhancement business by leveraging a powerful and proven AI/ML platform (trade name: bfLEAP™) initially developed at JHU-APL. We believe the bfLEAP™ analytics platform is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of Bullfrog AI Holdings, Inc. and our wholly owned subsidiaries and have been prepared in conformity with United States generally accepted accounting principles (“GAAP”) for interim financial information. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated statements are unaudited and should be read in conjunction with the consolidated financial statements and related notes included in our 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 25, 2023. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with the audited annual consolidated financial statements included in the 10-K and, in the opinion of management, include all adjustments of a normal recurring nature necessary to fairly state our financial position, our results of operations, and cash flows. The results for the nine months ended September 30, 2023 are not necessarily indicative of the operating results expected for the year ending December 31, 2023 or any other future period. On February 13, 2023, we completed a 1-for-7 reverse split of our common stock. Revenue Recognition The Company recognizes revenue based on the following five step model: - Identification of the contract with a customer This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services. - Identification of the performance obligations in the contract This step describes how distinct performance obligations in the contract must be handled. - Determination of the transaction price This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer. - Allocation of the transaction price to the performance obligations in the contract This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services. - Recognition of revenue when, or as, the Company satisfies a performance obligation Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen. Contract Services The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis. Once data analysis and the analysis report is complete, the Company delivers the analysis set to the customer and recognizes revenue at that point in time. Significant Accounting Policies There have been no new or material changes to the significant accounting policies discussed in the Company’s audited financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2022. Impact of Recently Issued Accounting Standards The Company has evaluated issued Accounting Standards Updates (“ASUs”) not yet adopted and believes the adoption of these standards will not have a material impact on its consolidated financial statements.	NOTE 2– SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Summary of Significant Accounting Policies Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates include, but are not limited to, revenue recognition, allowances for doubtful accounts, recoverability of deferred tax assets and certain other of our accrued liabilities. Actual results could differ from those estimates. Financial Instruments The carrying value of short-term instruments, including cash and cash equivalents, accounts payable and accrued expenses approximate fair value due to the relatively short period to maturity for these instruments. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a three-level valuation hierarchy for disclosures of fair value measurements, defined as follows: Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments. Level 3 - inputs to the valuation methodology are unobservable and significant to the fair value. The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis. Revenue Recognition For annual reporting periods after December 15, 2017, the Financial Accounting Standards Board (“FASB”) made effective ASU 2014-09 “Revenue from Contracts with Customers,” to supersede previous revenue recognition guidance under current U.S. GAAP. Revenue is now recognized in accordance with FASB ASC Topic 606, Revenue Recognition. The objective of the guidance is to establish the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. The core principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. Two options were made available for implementation of the standard: the full retrospective approach or modified retrospective approach. The guidance became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. We have adopted FASB ASC Topic 606 for our reporting period as of the year-ended December 31, 2019. As of December 31, 2021, we have had no 10,000 32,000 10,000 Revenue is recognized based on the following five step model: - Identification of the contract with a customer This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services - Identification of the performance obligations in the contract This step describes how distinct performance obligations in the contract must be handled - Determination of the transaction price This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer - Allocation of the transaction price to the performance obligations in the contract This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services - Recognition of revenue when, or as, the Company satisfies a performance obligation Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen Contract Services The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis. Collaborative Arrangements The Company also intends to enter collaborative arrangements with pharmaceutical companies who have drugs that have failed late Phase 2 or Phase 3 trials. These arrangements could take several forms including true partnerships where BullFrog contributes data analysis using the bfLEAP™ platform with the partner contributing the drug candidate and other resources needed to continue development towards commercialization with BullFrog receiving an equity or royalty right in the commercialized product. In other arrangements the Company may earn cash payments based on achieving certain milestones as determined under each specific arrangement. Acquisition of Rights to Certain Drugs In certain circumstances, we may also acquire rights to drugs that are in early-stage clinical trials, use our technology to sponsor and support a successful later stage precision medicine trial, and divest the asset. The same process may apply to the discovery of new drugs. In these instances, divestiture may be in the form of an outright sale of all rights or possibly a license to develop and commercialize enhanced development candidates. License agreements could include developmental and commercial milestones in addition to royalties. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Cash The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash. As of December 31, 2022 and 2021, cash balances were $ 57,670 10,014 Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis. Thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Allowance for Doubtful Accounts Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivables are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2022 and 2021, allowance for doubtful accounts was $ 0 Inventories The Company does not have inventory and does not plan to have inventory in the near future. Cost of Sales Cost of sales is comprised of royalties and the cost of outsourced services provided to the Company related to customer service contracts. We recognized $ 800 8% 10,000 Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives. Advertising The Company follows the policy of charging the costs of advertising to expense as incurred. Income Taxes Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized. The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of December 31, 2022 and 2021, the Company has not recorded any unrecognized tax benefits. Stock-Based Compensation Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. Net Loss per Share We compute net loss per share in accordance with ASC 260, Earning per Share. We report both basic and diluted loss per share. Loss earnings per share is calculated based on the weighted average number of shares of common stock outstanding and excludes the dilutive effect of warrants, stock options or any other type of convertible securities. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the contingently convertible notes and related dilutive shares are not included in the dilutive shares calculation upon the Initial Public Offering (IPO). Diluted loss per share is calculated based on the weighted average number of shares of common stock outstanding and the dilutive effect of stock options, warrants and other types of convertible securities are included in the calculation. Dilutive securities are excluded from the diluted earnings per share calculation because their effect is anti-dilutive. As of December 31, 2021 and December 31, 2022, 927,373 753,174 486,571 56,242 Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires lessees to recognize a lease liability, on a discounted basis, and a right-of-use asset for substantially all leases, as well as additional disclosures regarding leasing arrangements. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842), which provides an optional transition method of applying the new lease standard. Topic 842 can be applied using either a modified retrospective approach at the beginning of the earliest period presented, or as permitted by ASU 2018-11, at the beginning of the period in which it is adopted. We adopted this standard using a modified retrospective approach since inception of the company. The modified retrospective approach includes a number of optional practical expedients relating to the identification and classification of leases that commenced as of the inception of the company; initial direct costs for leases that commenced as of inception of the company; and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset. The Company elected the package of practical expedients permitted under ASC 842 allowing it to account for its prior operating lease that commenced before the adoption date as an operating lease under the new guidance without reassessing (i) whether the contract contains a lease; (ii) the classification of the lease; or (iii) the accounting for indirect costs as defined in ASC 842. All staff are working remotely; therefore, the Company does not currently have a lease or rent office space. Consistent with ASC 842-20-50-4, the Company’s financial statements for the years ended December 31, 2022 and 2021, do not have a monthly rent obligation. The Company had no cash flows arising from a lease, no finance lease cost, short term lease cost, or variable lease costs. The Company does not produce any sublease income or any net gain or loss recognized from sale and leaseback transactions. As a result, the Company did not need to segregate amounts between finance and operating leases for cash paid for amounts included in the measurement of lease liabilities, segregated between operating and financing cash flows; supplemental non-cash information on lease liabilities arising from obtaining right-of-use assets; weighted-average calculations for the remaining lease term; or the weighted-average discount rate. The adoption of this guidance resulted in no significant impact to the Company’s results of operations or cash flows. In December 2019, the FASB issued ASU No. 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 is part of the FASB’s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. The adoption of this update did not have a material effect on the Company’s financial statements. In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2021 including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. For all other entities, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of the fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The Company elected early adoption, effective January 1, 2021. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the convertible options are not considered to be readily convertible to cash. In addition, the beneficial conversion feature was eliminated under ASU 2020-06. Therefore, no derivative liabilities will be triggered from these convertible notes. In October 2020, the FASB issued ASU 2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC’s regulations. The Company adopted ASU 2020-10 as of the reporting period beginning January 1, 2021. The adoption of this update did not have a material effect on the Company’s financial statements. The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements. COVID-19 In March 2020, the World Health Organization declared the global emergence of the COVID-19 pandemic. The impact of COVID-19 on the Company’s business is currently unknown. The Company will continue to monitor guidance and orders issued by federal, state, and local authorities with respect to COVID-19. As a result, the Company may take actions that alter its business operations as may be required by such guidance and orders or take other steps that the Company determines are in the best interest of its employees, customers, partners, suppliers and stockholders. Any such alterations or modifications could cause substantial interruption to the Company’s business and could have a material adverse effect on the Company’s business, operating results, financial condition, and the trading price of the Company’s common stock, and could include temporary closures of one or more of the Company’s facilities; temporary or long-term labor shortages; temporary or long-term adverse impacts on the Company’s supply chain and distribution channels; and the potential of increased network vulnerability and risk of data loss resulting from increased use of remote access and removal of data from the Company’s facilities. In addition, COVID-19 could negatively impact capital expenditures and overall economic activity in the impacted regions or depending on the severity, globally, which could impact the demand for the Company’s products and services. It is unknown whether and how the Company may be impacted if the COVID-19 pandemic persists for an extended period of time or if there are increases in its breadth or in its severity, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which the Company is subject. The COVID-19 pandemic poses a risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period. The Company may incur expenses or delays relating to such events outside of its control, which could have a material adverse impact on its business, operating results, financial condition and the trading price of its common stock. Going Concern The Company has had negative cash flows from operations and operated at a net loss since inception. In the prior year our auditors included a paragraph in their opinion regarding the substantial doubt that existed of our ability to continue as a going concern. As noted in note 14 we completed our initial public offering subsequent to year end. We believe that the funds raised and notes that were converted from debt to equity now provides enough liquidity to alleviate the substantial doubt. There can be no assurance that we will not need additional funding in the future.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 3 – PROPERTY AND EQUIPMENT Property and Equipment Property and equipment consisted of the following: During the year ended December 31, 2022, the Company acquired $ 8,744 1,045 7,699 Depreciation expense totaled $ 1,045 0

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 4 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts Payable and Accrued Expenses As of December 31, 2022 and 2021, the Company had accounts payable and accrued expenses totaling $ 1,526,981 422,817

Notes Payable

Notes Payable	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable In January 2023 the Company entered into a short-term note payable with a principal balance of $ 100,000 20 9 In February 2023, the Company entered into an agreement to finance a portion of the premium for its Directors and Officers Insurance. The agreement provides for financing of $ 697,534 71,485 6.5 213,290 307,735	NOTE 5 – NOTES PAYABLE Notes Payable On May 5, 2020 the Company received an SBA PPP loan in the amount of $ 9,917 1%

Notes Payable Related Party

Notes Payable Related Party	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Notes Payable Related Party
Notes Payable Related Party	3. Notes Payable Related Party At various times in 2021, the Company entered into unsecured short term loan agreements with a related party for an aggregate principal balance of $ 49,000 5 1	NOTE 6 – NOTES PAYABLE RELATED PARTY Notes Payable Related Party On June 15, 2021, the company entered into an unsecured short term loan agreement with a related party for an aggregate principal balance of $ 34,000 5% 1% On November 19, 2021, 2021, the company entered into an unsecured short term loan agreement with a related party for an aggregate principal balance of $ 5,000 5% 1% On December 13, 2021, the company entered into an unsecured short term loan agreement with a related party for an aggregate principal balance of $ 10,000 5% 1%

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Convertible Notes Payable	4. Convertible Notes Convertible Notes Payable March 2020 Note On March 27, 2020, the Company entered into a convertible loan agreement with the Maryland Technology Development Corporation with a principal balance of $ 200,000 6 September 27, 2021 226,138 205,984 5,000,000 August 2021 Note In August 2021, the Company entered into a convertible loan agreement with an unrelated party for a commitment of up to $ 195,000 5 9 February 9, 2022 72,000 123,000 20 As December 31, 2022, the loan was outstanding with a principal balance of $ 195,000 35,078 In connection with the convertible loan agreement, the Company also issued 195,000 1.00 five years 225,000 2.50 December 2021 Note On December 20, 2021, the Company entered into a loan agreement with an unrelated party. The loan provided for a December 19, 2022 10 6 25,000 The note was automatically convertible into shares of common stock at a discount to the IPO price or based on the valuation of the Company, whichever was more favorable to the holder. Initially, the loan was estimated to be issued with 355,114 1 Concurrent with the closing of the Company’s IPO, the note converted according to its terms into 6,939 Convertible Bridge Notes On April 11, 2022, the Company entered into an Exclusive placement agent and/or underwriter agreement with WallachBeth Capital LLC in connection with a proposed private and/or public offerings by the Company. On April 28, 2022, the Company received approximately $ 775,000 91,000 10 100,000 25,000 10 The Convertible Bridge Notes were initially convertible at the IPO at a 20 In connection with the Convertible Bridge Notes, the purchasers were also entitled to conditional warrants to be issued upon completion of the Company’s IPO. The agreement provided for the warrants to be exercisable for a period of five years from issuance at an exercise price equal to 110% of the IPO price or, if the Company failed to complete the IPO before October 22, 2022, 90% of the IPO price. In the fourth quarter of 2022, the Company amended the Convertible Bridge Notes to (a) extend the maturity date until December 31, 2022, (b) provide that the conversion right would include interest through November 30, 2022, with interest accruing beyond that date being paid in cash and (c) revise the conversion price to be $ 4.27 25 4.27 Concurrent with the closing of the Company’s IPO in February 2023, all of the Convertible Bridge Notes converted according to their terms into 269,513	NOTE 7 – CONVERTIBLE NOTES PAYABLE Convertible Notes Payable On March 27, 2020, the company entered into a convertible loan agreement with the Maryland Technology Development Corporation with a principal balance of $ 200,000 6% September 27, 2021 226,138 205,984 5,000,000 On August 9, 2021, the company entered into a convertible loan agreement with an unrelated party to loan up to $ 195,000 9% 72,000 5% 195,000 1 5 February 9, 2022 123,000 6,150 225,000 2.50 195,000 35,078 8,393 0 64,978 On December 20, 2021, the company entered into a loan agreement with an unrelated party, with a principal balance of $ 25,000 6% December 19, 2022 2,778 10% 2,301 355,114 1 On April 11, 2022, the Company entered into an Exclusive placement agent and/or underwriter agreement with WallachBeth Capital LLC in connection with a proposed private and/or public offerings by the Company. As discussed in Footnote 2, a significant component of the Company’s plan to secure capital is the intention of the Company to seek to be listed on a national exchange through an initial public offering (“IPO”) of its common stock. WallachBeth was engaged in this regard and on April 28, 2022, the Company received net proceeds of approximately $ 775,000 91,560 100,000 27,779 10% 20% The purchasers will also be issued a warrant for each share of common stock issued upon conversion of the Note at a price equal to 110% of the IPO price or, if the Company fails to complete the IPO before October 22, 2022, 90% of the IPO price. October 31, 2022 December 31, 2022 25 4.27 As of December 31, 2022, the table below reflects the balances of the Convertible Bridge Notes sold pursuant April 11, 2022 agreement with WallachBeth. All notes are mandatorily converted at the IPO at the conversion ratio noted above and the purchasers will also be issued a warrant for each share of common stock issued upon conversion with an exercise price set by the exchange ratio. Due to the IPO price not yet being probable at year end, no current accounting for these warrants has been journalized. Schedule of Convertible Debt Note Date Purchase Price Principal Balance Original Issue Discount Accrued Interest Note Purchase Principal Original Issue Accrued Date Price Balance Discount Interest 4/28/2022 $ 250,000 $ 277,778 $ 27,778 $ 17,083 4/28/2022 $ 250,000 $ 277,778 $ 27,778 $ 17,083 4/28/2022 $ 250,000 $ 277,778 $ 27,778 $ 17,083 4/28/2022 $ 25,000 $ 27,778 $ 2,778 $ 1,708 4/28/2022 $ 28,000 $ 31,111 $ 3,111 $ 1,913 4/28/2022 $ 28,000 $ 31,111 $ 3,111 $ 1,913 4/28/2022 $ 35,000 $ 38,889 $ 3,889 $ 2,392 12/20/2021 $ 25,000 $ 27,778 $ 2,778 $ 2,301 4/13/2022 $ 100,000 $ 111,111 $ 11,111 $ 7,111 9/9/2022 $ 25,000 $ 27,778 $ 2,778 $ 1,088 Total $ 1,016,000 $ 1,128,889 $ 112,889 $ 69,675 * Notes sold by Company prior to the April 28, 2022 closing In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. The Company specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. After adoption of ASU 2020-06, if the equity securities underlying the conversion option are not readily convertible to cash, and the conversion option requires gross physical settlement of the underlying shares, the embedded conversion option may not meet the net settlement criterion, and therefore would not meet the definition of a derivative. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the convertible options are not considered to be readily convertible to cash. In addition, the beneficial conversion feature was eliminated under ASU 2020-06. Therefore, no derivative liabilities will be triggered from these convertible notes. All conversions are contingent upon an effective IPO, which had not yet been considered probable.

Convertible Notes Payable Relat

Convertible Notes Payable Related Party	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Convertible Notes Payable Related Party
Convertible Notes Payable Related Party	5. Convertible Notes – Related Party Convertible Notes Payable Related Party SAFE Agreement On July 8, 2021, the Company entered into a Simple Agreement for Future Equity (SAFE), with a related party, at a purchase price of $ 150,000 In February 2023, the SAFE terminated and converted into 32,967 63,626 As of December 31, 2022, the $ 150,000 6 August 2021 Note On August 19, 2021, the Company entered into a convertible loan agreement with a related party, with a principal balance of $ 99,900 5 9 February 19, 2022 In February 2023, the related party elected to convert the convertible loan into 21,747 29,333 In connection with the convertible loan agreement, the Company also issued 99,000 1.00 115,185 2.50	NOTE 8 – CONVERTIBLE NOTES PAYABLE RELATED PARTY Convertible Notes Payable Related Party On July 8, 2021, the company entered into a Simple Agreement for Future Equity (SAFE), with a related party, with an amount of $ 150,000 , with 0 % interest. Under the SAFE agreement, if there is an Equity Financing before the termination of this SAFE , on the initial closing of such Equity Financing, this SAFE will automatically convert into the number of shares of SAFE Preferred Stock equal to the Purchase Amount divided by the Conversion Price, which means either: (1) the Safe Price (the price per share equal to the Post-Money Valuation Cap divided by the Company If there is a Liquidity Event before the termination of this SAFE , this SAFE will automatically be entitled (subject to the liquidation priority set forth in Section 1(d) below) to receive a portion of Proceeds, due and payable to the Investor immediately prior to, or concurrent with, the consummation of such Liquidity Event, equal to the greater of (i) the Purchase Amount (the “Cash-Out Amount”) or (ii) the amount payable on the number of shares of Common Stock equal to the Purchase Amount divided by the Liquidity Price (the “Conversion Amount”). If any of the Company’s securityholders are given a choice as to the form and amount of Proceeds to be received in a Liquidity Event, the Investor will be given the same choice, provided that the Investor may not choose to receive a form of consideration that the Investor would be ineligible to receive as a result of the Investor’s failure to satisfy any requirement or limitation generally applicable to the Company’s securityholders, or under any applicable laws. This SAFE will automatically terminate (without relieving the Company of any obligations arising from a prior breach of or non-compliance with this SAFE ) immediately following the earliest to occur of: (i) the issuance of Capital Stock to the Investor pursuant to the automatic conversion of this SAFE under agreement; or (ii) the payment, or setting aside for payment, of amounts due the Investor pursuant to the agreement. As of December 31, 2022 and 2021, the $ 150,000 6 On August 19, 2021, the company entered into a convertible loan agreement with a related party, with a principal balance of $ 99,900 9 5 99,900 1 5 February 19, 2022 115,185 2.50 99,900 4,950 12,463.53 The SAFE and the convertible loan agreement with accrued interest converted to common stock at the IPO. The Company specified that an entity should adopt ASU 2020-06 as of the beginning of its annual fiscal year. After adoption of ASU 2020-06, no derivative liabilities will be triggered from these convertible notes. See Note 7 for details.

Related Party

Related Party	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party	7. Related Party During the nine months ended September 30, 2023, the Company issued 75,000 During the year ended December 31, 2021, the Company issued 29,286 10 430 450 1,290 1,350	NOTE 9 – RELATED PARTY Related Party During the year-ended December 31, 2021, there were 57,143 As of December 31, 2022 and 2021, the accrued salary for related parties was $ 566,916 285,666 As of December 31, 2022, the Company accrued consulting fees to related parties of $ 90,000 During the year ended December 31, 2021, the Company issued options totaling 29,286 The options have an original life of ten years and vest at different rates over as much as 24 months. During the year ended December 31, 2022, the Company did not issue any options and recognized $ 1,803

Stockholder_s Equity

Stockholder’s Equity	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Equity [Abstract]
Stockholder’s Equity	8. Stockholder’s Equity Preferred Stock The Company has 10,000,000 0.00001 5,500,000 734,492 73,449 10 315,000 Common Stock The Company has 100,000,000 0.00001 ● Exchanged 734,429 ● Issued 205,984 226,138 ● Cancelled 112,225 ● Issued 38,879 189,828 After the Company signed two licenses for two drug programs from universities in the first half of 2022 it engaged an independent valuation firm to perform an Enterprise-Equity valuation. The results of this engagement resulted in an increase in the value per share of common stock used in the Black Scholes option pricing model employed to value the Company’s equity grants and warrant issuances. In February 2023, the Company completed its IPO for the sale of 1,297,318 6.50 8.4 Each Unit consisted of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $ 7.80 non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $ 8.125 In connection with the completion of its IPO, the Company issued an aggregate of 331,166 In connection with the IPO, in February 2023, the Company completed a 1-for-7 reverse split of our common stock. In February 2023, the Company issued 7,692 50,000 In the second quarter of 2023, we issued 436,533 436,533 1,494,658 Dilutive securities are excluded from the diluted earnings per share calculation because their effect is anti-dilutive. As of September 30, 2023, 3,796,164 507,717 5,270,617 484,525 2022 Equity Incentive Plan In November 2022, the Company’s Board of Directors adopted, and its shareholders approved the 2022 Equity Incentive Plan (the “Plan”). The Plan provides for the granting of equity-based awards to employees, directors, and consultants. The Plan provides for equity-based awards including incentive stock options, non-qualified stock options, stock appreciation rights, performance share awards, cash awards and other equity-based awards. Awards are limited to a maximum term of 10 900,000 15 461,500 Stock Options The following table summarizes the stock option activity for the nine months ended September 30, 2023: Schedule of Stock Options Activity Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at December 31, 2022 69,217 $ 3.06 7.08 $ 117,669 Granted 438,500 $ 4.41 - $ - Exercised - $ - - $ - Forfeited / canceled - $ - - $ - Outstanding at September 30, 2023 507,717 $ 4.23 9.17 $ 102,441 Vested at September 30, 2023 215,623 $ 3.97 8.64 $ 52,644 The fair value of options granted in the nine months ended September 30, 2023 were estimated using the Black-Scholes option pricing model based on the assumptions in the table below: Schedule of Black Scholes Option Pricing Model 2023 Expected dividend yield 0% Expected volatility 87 92% Risk-free interest rate 3.4 4.1 Expected life (in years) 5.0 6.0 The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2023 was $ 3.20 No options were exercised in any of the periods presented. During the three and nine months ended September 30, 2023, the Company recognized $ 116,410 475,465 51,536 290,876 As of September 30, 2023, the total unrecognized compensation expense related to unvested stock options, was approximately $ 936,000 2.1 Warrants During the nine months ended September 30, 2023 and 2022, the Company granted a total of 3,195,906 56,623 The warrants have an original life of ten years and vest immediately and over 12 months. 22,939 35,712 174,105 337,269 51,941 11,097 42,057 1,883 During the year ended December 31, 2021, the Company granted a total of 431,659 200,000 12,462 0 200,000 138,929 28,683 The warrants have an original life of ten years and vest at different rates over as much as 36 months. During the year ended December 31, 2021, the Company issued 92,859 12,980 five years 50,735 11,097 99,000 115,185 2.50 1 15,412 195,000 225,000 2.50 64,978 The 92,859 During the nine months ended September 30, 2023, the Company issued the following warrants: ● In February 2023, in connection with the completion of the initial public offering, the Company issued 276,452 4.27 5 ● In February 2023, in connection with the completion of the initial public offering, the Company issued 18,000 8.125 4 ● As part of the sale of units in the Company’s initial public offering the Company issued 1,297,318 7.80 5 1,297,318 8.125 5 ● In February 2023, as part of the Company’s initial public offering, the Company issued 153,409 7.80 5 153,409 8.125 5 During the three and nine months ended September 30, 2023, the Company recognized $ 5,050 35,712 51,086 289,317 6,556 0.4 The following table provides details over the Company’s outstanding warrants as of September 30, 2023: Schedule of Outstanding Warrants Exercise Price Expiration Number of Warrants $ 0.0007 2030 274,286 $ 2.10 2.66 2026 2032 460,445 $ 3.36 4.27 2028 2029 115,277 $ 6.51 7.80 2026 2032 1,484,929 $ 8.125 2027 2028 1,461,227 3,796,164	NOTE 10– SHAREHOLDER’S DEFICT Stockholder’s Equity The Company has 10,000,000 0.00001 no 734,492 73,449 10 he Company evaluated the terms of the exchange and determined there would be no significant change in fair value and therefore no accounting entry recorded as a result of the exchange. The value of the Series A Preferred Stock was determined to be $ 315,000 Common Stock In June of 2020, BullFrog AI Holdings, Inc. acquired BullFrog AI, Inc. via a 1:1 share exchange. Immediately prior to the share exchange, each authorized common share of BullFrog AI, Inc. was split into 25 shares of common stock The Company has 100,000,000 0.00001 734,492 205,984 226,138 112,225 38,879 189,828 4,021,935 4,622,789 After the Company signed two licenses for two drug programs from universities in the first half of 2022 it engaged an independent valuation firm to perform an Enterprise-Equity valuation. The results of this engagement resulted in an increase in the value per share of common stock used in the Black Scholes option pricing model employed to value the Company’s equity grants and warrant issuances. Our Board of Directors and stockholders approved an amendment to our Certificate of Incorporation to effect a 1-for-7 reverse stock split Stock Options During the first quarter of 2022, 399,354 (post reverse stock split) During the year ended December 31, 2021, the Company granted a total of 29,286 ten years 48 months 1,310 157 16,601 2,010 The following tables summarizes the stock options (post reverse stock split) activity for the years ended December 31, 2022 and 2021: Schedule of Stock Options Activity Granted and outstanding, December 31, 2020 884,821 Granted during 2021 29,286 Exercised - Forfeited - Expired during 2021 (445,536 ) Granted and outstanding, December 31, 2021 468,571 Granted during 2022 - Exercised - Forfeited (399,354 ) Expired during 2022 - Granted and outstanding, December 31, 2022 69,217 Schedule of Vested and Outstanding Options Options Intrinsic Value of Vested Options Weight Averaged exercise Price Vested and outstanding, December 31, 2020 104,795 12,706 3.36 Granted and vested during 2021 1,310 157 2.66 Exercised - - - Forfeited - - - Expired (66,524 ) (7,922 ) (3.36 ) Vested and outstanding, December 31, 2021 39,581 4,941 3.36 Granted and vested during 2022 16,661 2,010 2.73 Exercised - - - Forfeited - - - Expired - - - Vested and outstanding, December 31, 2022 56,242 6,951 3.15 As of December 31, 2022 and 2021, 16,661 1,310 0 66,524 7.08 7.38 As of December 31, 2022 and 2021, the fair value of options vested and outstanding was $ 6,951 4,941 Schedule of Black Scholes Option Pricing Model December 31, 2022 December 31, 2021 Fair Value of Common Stock on measurement date $ 4.76 $ 0.308 Risk free interest rate From 0.79 3.01 % From 1.26 1.33 % Volatility 89 % 93 % Dividend Yield 0 % 0 % Expected Term 4 10 10 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future. Warrants During the year ended December 31, 2022, the Company granted a total of 123,660 (post reverse stock split) The warrants have an original life of four to ten years and vest immediately and over 12 months. 174,105 (post reverse stock split) 337,269 51,941 11,097 42,057 During the year ended December 31, 2021, the Company granted a total of 431,659 (post reverse stock split) 200,000 (post reverse stock split) 12,462 The warrants have an original life of five years and vest 30 days before the intended IPO 0 200,000 (post reverse stock split) cancelled and voided per agreement of the warrant holder and the Company. There was no gain or loss due to cancellation. 138,929 (post reverse stock split) 28,683 The warrants have an original life of ten years and vest at different rates over as much as 36 months. During the year ended December 31, 2021, the Company issued 92,859 (post reverse stock split) 12,980 five years 50,735 (post reverse stock split) 11,097 As discussed in Note 8 in May 2022, the Company and the note holders agreed to cancel and void the previous 99,000 115,185 2.50 1 15,412 . As discussed in Note 8 in May 2022, the Company and the note holders agreed to cancel and void the previous 195,000 225,000 2.50 64,978 . The 92,859 The following tables summarize the warrant activity (post reverse stock split) for the year ended December 31, 2022 and 2021, Schedule of Stock Warrant Activity Warrants Granted and outstanding, December 31, 2020 495,714 Granted during 2021 431,659 Exercised - Forfeited - Expired during 2021 - Granted and outstanding, December 31, 2021 927,373 Granted during 2022 123,660 Exercised - Forfeited (298,088 ) Expired during 2022 - Granted and outstanding, December 31, 2022 752,945 Schedule of Vested And Outstanding Warrants Warrants Intrinsic Value of Warrants Weight Averaged exercise Price Vested and outstanding, December 31, 2020 479,940 127,480 0.98 Granted and Vested 2021 137,552 22,208 3.15 Exercised - - - Forfeited - - - Expired - - - Vested and outstanding, December 31, 2021 617,492 149,688 2.80 Granted and Vested 2022 174,105 337,263 3.15 Exercised - - - Forfeited (94,665 ) (12,980 ) - Expired - - - Vested and outstanding, December 31, 2022 696,932 473,971 1.96 As of December 31, 2022, 752,945 (post reverse stock split) 696,932 (post reverse stock split) 7.13 For the year ended December 31, 2022, the aggregate fair value of warrants vested was $ 324,283 For the year ended December 31, 2021, 927,516 617,492 22,208 7.73 As of December 31, 2021, the aggregate fair value of warrants vested was $ 149,688 The number of warrants related to the Convertible Bridge Notes discussed Note 7 is not yet determinable, given some of the terms discussed in Note 8 have not been completed. Therefore, the warrants to be issued are not accounted for in our warrants outstanding. Due to the IPO price not being completed at December 31, 2022, no current accounting for these warrants has been journalized. Schedule of Black Scholes Option Pricing Model December 31, 2022 December 31, 2021 Fair Value of Common Stock on measurement date $ 4.76 $ 0.308 Risk free interest rate From 1.86 1.97 % From 0.78 1.63 % Volatility 89 % 93 % Dividend Yield 0 % 0 % Expected Term 10 5 10 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future. (4) After the Company signed two licenses for two drug programs from universities in the first half of 2022 it engaged an independent valuation firm to perform an Enterprise-Equity valuation. The results of this engagement resulted in an increase in the value per share of common stock used in the Black Scholes option pricing model employed to value the Company’s equity grants and warrant issuances for all 2022 grant date stock prices. The following table provides details over the Company’s outstanding warrants as of September 30, 2023: Schedule of Outstanding Warrants Exercise Price Expiration Number of Warrants $ 0.0007 2030 274,286 $ 2.10 2.66 2026 2032 460,445 $ 3.36 4.27 2028 2029 115,277 $ 6.51 7.80 2026 2032 1,484,929 $ 8.125 2027 2028 1,461,227 3,796,164

Income Taxes

Income Taxes	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes The Company has not recorded any tax provision or benefit for the three and nine months ended September 30, 2023 and 2022. The Company has provided a valuation allowance for the full amount of its net deferred tax assets since realization of any future benefits from deductible temporary differences, net operating loss carryforwards and research and development credits are not more-likely-than-not to be realized at September 30, 2023 and December 31, 2022.	NOTE 11 – INCOME TAXES Income Taxes As of December 31, 2022, the Company has available for federal income tax purposes a net operating loss carry forward of approximately $ 4,399,055 We have adopted the provisions of ASC 740-10-25, which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. ASC 740-10-25 requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. Tax position that meets the more likely than not threshold is then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company had no tax positions relating to open income tax returns that were considered to be uncertain. We file income tax returns in the U.S. and in the state of California and Utah with varying statutes of limitations. The Company’s deferred taxes as of December 31, 2022 and 2021 consist of the following: Schedule of Deferred Taxes 2022 2021 Non-Current deferred tax asset: Net operating loss carryforwards $ 924,000 $ 339,000 Valuation allowance (924,000 ) (339,000 ) Net non-current deferred tax asset $ — $ —

Material Agreements

Material Agreements	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Material Agreements
Material Agreements	10. Material Agreements JHU-APL Technology License On February 7, 2018, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the technology. The license covers three (3) issued patents, one (1) new provisional patent application, non-patent rights to proprietary libraries of algorithms and other trade secrets, the license also includes modifications and improvements. In October of 2021, the Company executed an amendment to the original license which represents improvements and new advanced analytics capabilities. In consideration of the rights granted to the Company under the License Agreement JHU received a warrant equal to five percent ( 5 8 50 1,500 20,000 80,000 300,000 279,159 8 3 50 25 30,000 60,000 300,000 On May 31, 2023, the Company and JHU-APL entered into Amendment number 1 of the July 8, 2022 License Agreement whereby the Company gained access to certain improvements including additional patents and knowhow in exchange for a series of payments totaling $ 275,000 75,000 75,000 75,000 50,000 60,000 45,000 George Washington University - Beta2-spectrin siRNA License On January 14, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from George Washington University (GWU) for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma (HCC). The license covers methods claimed in three US and worldwide patent applications, and also includes use of this approach for treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. In consideration of the rights granted to the Company under the License Agreement the Company paid GWU a $ 20,000 3 no Johns Hopkins University – Mebendazole License On February 22, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from Johns Hopkins University (JHU) for the use of an improved formulation of Mebendazole for the treatment of any human cancer or neoplastic disease. This formulation shows potent activity in animal models of different types of cancer and has been evaluated in a Phase I clinical trial in patients with high-grade glioma (NCT01729260). The trial, an open-label dose-escalation study, assessed the safety and efficacy of the improved formulation with adjuvant temozolomide in 24 patients with newly diagnosed gliomas. Investigators observed no dose-limiting toxicity in patients receiving all but the highest tested dose (200mg/kg/day). Four of the 15 patients receiving the maximum tested dose of 200mg/kg/day experienced dose-limiting toxicity, all of which were reversed by decreasing or eliminating the dose given. There were no serious adverse events attributed to Mebendazole at any dose during the trial. 41.7% of patients who received Mebendazole were alive at two years after enrollment, and 25% were alive at four years (Gallia et al., 2021). The license covers six (6) issued patents and one (1) pending application. In consideration of the rights granted to the Company under the License Agreement, JHU will receive a staggered Upfront License Fee of $ 250,000 50,000 200,000 3.5 5,000 10,000 20,000 30,000 50,000 250,000 7,500 242,671 Johns Hopkins University – Prodrug License On October 13, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU and the Institute of Organic Chemistry and Biochemistry (IOCB) of the Czech Academy of Sciences for rights to commercialize N-substituted prodrugs of Mebendazole that demonstrate improved solubility and bioavailability. The license covers prodrug compositions and use for treating disease as claimed in multiple US and worldwide patent applications. In consideration for the rights granted to the Company under the License Agreement JHU and IOCB will receive a staggered upfront license fee of $ 100,000 4.0 5,000 10,000 20,000 30,000 50,000 150,000 0 133,238	NOTE 12 – MATERIAL AGREEMENTS Material Agreements JHU-APL Technology License On February 7, 2018, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the technology. The license covers three (3) issued patents, 1 new provisional patent application, non-patent rights to proprietary libraries of algorithms and other trade secrets, the license also includes modifications and improvements. In October of 2021, the Company executed an Amendment to the original license which represents improvements and new advanced analytics capabilities. In consideration of the rights granted to the Company under the License Agreement JHU received a warrant equal to five ( 5% 8% 50% 1,500 20,000 80,000 300,000 st 279,159 8% 3% 50% 25% 30,000 80,000 300,000 30,000 George Washington University - Beta2-spectrin siRNA License On January 14, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from George Washington University (GWU) for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma (HCC). The license covers methods claimed in three US and worldwide patent applications, and also includes use of this approach for treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. In consideration of the rights granted to the Company under the License Agreement GWU received a $ 20,000 3% Johns Hopkins University – Mebendazole License On February 22, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from Johns Hopkins University (JHU) for the use of an improved formulation of Mebendazole for the treatment of any human cancer or neoplastic disease. This formulation shows potent activity in animal models of different types of cancer and has been evaluated in a Phase I clinical trial in patients with high-grade glioma (NCT01729260). The trial, an open-label dose-escalation study, assessed the safety and efficacy of the improved formulation with adjuvant temozolomide in 24 patients with newly diagnosed gliomas. Investigators observed no dose-limiting toxicity in patients receiving all but the highest tested dose (200mg/kg/day). Four of the 15 patients receiving the maximum tested dose of 200mg/kg/day experienced dose-limiting toxicity, all of which were reversed by decreasing or eliminating the dose given. There were no serious adverse events attributed to mebendazole at any dose during the trial. 41.7% of patients who received mebendazole were alive at two years after enrollment, and 25% were alive at four years (Gallia et al., 2021). The license covers six (6) issued patents and one (1) pending application. In consideration of the rights granted to the Company under the License Agreement JHU will receive a staggered Upfront License Fee of $ 250,000 3.5% 5,000 10,000 20,000 30,000 50,000 250,000 250,000 50,000 10 242,671 Johns Hopkins University – Prodrug License On October 13, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from Johns Hopkins University (JHU) and the Institute of Organic Chemistry and Biochemistry (IOCB) of the Czech Academy of Sciences for rights to commercialize N-substituted prodrugs of mebendazole that demonstrate improved solubility and bioavailability. The license covers prodrug compositions and use for treating disease as claimed in multiple US and worldwide patent applications. In consideration for the rights granted to the Company under the License Agreement JHU and IOCB will receive a staggered upfront license fee of $ 100,000 . The Company will also reimburse JHU and IOCB for previously incurred patent costs. Under the terms of the License Agreement, JHU and IOCB will be entitled to four percent ( 4.0% ) royalty on net sales by the Company. In addition, the Company is required to pay JHU and IOCB minimum annual royalty payments of $ 5,000 for 2027, $ 10,000 for 2028, $ 20,000 for 2029, $ 30,000 for 2030 and $ 50,000 for 2031 and each year after until the first commercial sale after which the annual minimum royalty shall be $ 150,000 . The license agreement also contains milestone payments for patent grants, clinical development steps through the approval of an NDA and commercialization. As of December 31, 2022, the balance of accrued expense related to this license agreement was $ 133,238

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 13 – COMMITMENTS AND CONTINGENCIES Commitments and Contingencies The Company follows ASC 450, Contingencies, which requires the Company to assess the likelihood that a loss will be incurred from the occurrence or non-occurrence of one or more future events. Such assessment inherently involves an exercise of judgment. In assessing possible loss contingencies from legal proceedings or unasserted claims, the Company evaluates the perceived merits of such proceedings or claims, and of the relief sought or expected to be sought. If the assessment of a contingency indicates that it is probable that a material loss will be incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. While not assured, management does not believe, based upon information available at this time, that a loss contingency will have material adverse effect on the Company’s financial position, results of operations or cash flows.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	NOTE 14 – SUBSEQUENT EVENTS Subsequent Events On February 14, 2023 the Company conducted its initial public offering of 1,297,318 6.50 8.4 Each Unit consists of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $ 7.80 one non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $ 8.125 In connection with the offering, the Company common shares were subject to a 1-7 reverse stock split - 1 share of new common for 7 shares then outstanding common stock 55,787 276,289 276,289 $25 Between April 5 and April 13, 2023, the holders of warrants exercised 436,533 1,495,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Use of Estimates in the Preparation of Financial Statements		Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates include, but are not limited to, revenue recognition, allowances for doubtful accounts, recoverability of deferred tax assets and certain other of our accrued liabilities. Actual results could differ from those estimates.
Financial Instruments		Financial Instruments The carrying value of short-term instruments, including cash and cash equivalents, accounts payable and accrued expenses approximate fair value due to the relatively short period to maturity for these instruments. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a three-level valuation hierarchy for disclosures of fair value measurements, defined as follows: Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments. Level 3 - inputs to the valuation methodology are unobservable and significant to the fair value. The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis.
Revenue Recognition	Revenue Recognition The Company recognizes revenue based on the following five step model: - Identification of the contract with a customer This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services. - Identification of the performance obligations in the contract This step describes how distinct performance obligations in the contract must be handled. - Determination of the transaction price This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer. - Allocation of the transaction price to the performance obligations in the contract This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services. - Recognition of revenue when, or as, the Company satisfies a performance obligation Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen.	Revenue Recognition For annual reporting periods after December 15, 2017, the Financial Accounting Standards Board (“FASB”) made effective ASU 2014-09 “Revenue from Contracts with Customers,” to supersede previous revenue recognition guidance under current U.S. GAAP. Revenue is now recognized in accordance with FASB ASC Topic 606, Revenue Recognition. The objective of the guidance is to establish the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. The core principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. Two options were made available for implementation of the standard: the full retrospective approach or modified retrospective approach. The guidance became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. We have adopted FASB ASC Topic 606 for our reporting period as of the year-ended December 31, 2019. As of December 31, 2021, we have had no 10,000 32,000 10,000 Revenue is recognized based on the following five step model: - Identification of the contract with a customer This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services - Identification of the performance obligations in the contract This step describes how distinct performance obligations in the contract must be handled - Determination of the transaction price This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer - Allocation of the transaction price to the performance obligations in the contract This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services - Recognition of revenue when, or as, the Company satisfies a performance obligation Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen Contract Services The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis. Collaborative Arrangements The Company also intends to enter collaborative arrangements with pharmaceutical companies who have drugs that have failed late Phase 2 or Phase 3 trials. These arrangements could take several forms including true partnerships where BullFrog contributes data analysis using the bfLEAP™ platform with the partner contributing the drug candidate and other resources needed to continue development towards commercialization with BullFrog receiving an equity or royalty right in the commercialized product. In other arrangements the Company may earn cash payments based on achieving certain milestones as determined under each specific arrangement. Acquisition of Rights to Certain Drugs In certain circumstances, we may also acquire rights to drugs that are in early-stage clinical trials, use our technology to sponsor and support a successful later stage precision medicine trial, and divest the asset. The same process may apply to the discovery of new drugs. In these instances, divestiture may be in the form of an outright sale of all rights or possibly a license to develop and commercialize enhanced development candidates. License agreements could include developmental and commercial milestones in addition to royalties.
Use of Estimates		Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Cash		Cash The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash. As of December 31, 2022 and 2021, cash balances were $ 57,670 10,014
Concentrations of Credit Risk		Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.
Accounts Receivable		Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis. Thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.
Allowance for Doubtful Accounts		Allowance for Doubtful Accounts Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivables are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2022 and 2021, allowance for doubtful accounts was $ 0
Inventories		Inventories The Company does not have inventory and does not plan to have inventory in the near future.
Cost of Sales		Cost of Sales Cost of sales is comprised of royalties and the cost of outsourced services provided to the Company related to customer service contracts. We recognized $ 800 8% 10,000
Property and Equipment		Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives.
Advertising		Advertising The Company follows the policy of charging the costs of advertising to expense as incurred.
Income Taxes		Income Taxes Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized. The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of December 31, 2022 and 2021, the Company has not recorded any unrecognized tax benefits.
Stock-Based Compensation		Stock-Based Compensation Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period.
Net Loss per Share		Net Loss per Share We compute net loss per share in accordance with ASC 260, Earning per Share. We report both basic and diluted loss per share. Loss earnings per share is calculated based on the weighted average number of shares of common stock outstanding and excludes the dilutive effect of warrants, stock options or any other type of convertible securities. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the contingently convertible notes and related dilutive shares are not included in the dilutive shares calculation upon the Initial Public Offering (IPO). Diluted loss per share is calculated based on the weighted average number of shares of common stock outstanding and the dilutive effect of stock options, warrants and other types of convertible securities are included in the calculation. Dilutive securities are excluded from the diluted earnings per share calculation because their effect is anti-dilutive. As of December 31, 2021 and December 31, 2022, 927,373 753,174 486,571 56,242
Impact of Recently Issued Accounting Standards	Impact of Recently Issued Accounting Standards The Company has evaluated issued Accounting Standards Updates (“ASUs”) not yet adopted and believes the adoption of these standards will not have a material impact on its consolidated financial statements.	Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires lessees to recognize a lease liability, on a discounted basis, and a right-of-use asset for substantially all leases, as well as additional disclosures regarding leasing arrangements. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842), which provides an optional transition method of applying the new lease standard. Topic 842 can be applied using either a modified retrospective approach at the beginning of the earliest period presented, or as permitted by ASU 2018-11, at the beginning of the period in which it is adopted. We adopted this standard using a modified retrospective approach since inception of the company. The modified retrospective approach includes a number of optional practical expedients relating to the identification and classification of leases that commenced as of the inception of the company; initial direct costs for leases that commenced as of inception of the company; and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset. The Company elected the package of practical expedients permitted under ASC 842 allowing it to account for its prior operating lease that commenced before the adoption date as an operating lease under the new guidance without reassessing (i) whether the contract contains a lease; (ii) the classification of the lease; or (iii) the accounting for indirect costs as defined in ASC 842. All staff are working remotely; therefore, the Company does not currently have a lease or rent office space. Consistent with ASC 842-20-50-4, the Company’s financial statements for the years ended December 31, 2022 and 2021, do not have a monthly rent obligation. The Company had no cash flows arising from a lease, no finance lease cost, short term lease cost, or variable lease costs. The Company does not produce any sublease income or any net gain or loss recognized from sale and leaseback transactions. As a result, the Company did not need to segregate amounts between finance and operating leases for cash paid for amounts included in the measurement of lease liabilities, segregated between operating and financing cash flows; supplemental non-cash information on lease liabilities arising from obtaining right-of-use assets; weighted-average calculations for the remaining lease term; or the weighted-average discount rate. The adoption of this guidance resulted in no significant impact to the Company’s results of operations or cash flows. In December 2019, the FASB issued ASU No. 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 is part of the FASB’s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. The adoption of this update did not have a material effect on the Company’s financial statements. In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2021 including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. For all other entities, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of the fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The Company elected early adoption, effective January 1, 2021. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the convertible options are not considered to be readily convertible to cash. In addition, the beneficial conversion feature was eliminated under ASU 2020-06. Therefore, no derivative liabilities will be triggered from these convertible notes. In October 2020, the FASB issued ASU 2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC’s regulations. The Company adopted ASU 2020-10 as of the reporting period beginning January 1, 2021. The adoption of this update did not have a material effect on the Company’s financial statements. The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.
COVID-19		COVID-19 In March 2020, the World Health Organization declared the global emergence of the COVID-19 pandemic. The impact of COVID-19 on the Company’s business is currently unknown. The Company will continue to monitor guidance and orders issued by federal, state, and local authorities with respect to COVID-19. As a result, the Company may take actions that alter its business operations as may be required by such guidance and orders or take other steps that the Company determines are in the best interest of its employees, customers, partners, suppliers and stockholders. Any such alterations or modifications could cause substantial interruption to the Company’s business and could have a material adverse effect on the Company’s business, operating results, financial condition, and the trading price of the Company’s common stock, and could include temporary closures of one or more of the Company’s facilities; temporary or long-term labor shortages; temporary or long-term adverse impacts on the Company’s supply chain and distribution channels; and the potential of increased network vulnerability and risk of data loss resulting from increased use of remote access and removal of data from the Company’s facilities. In addition, COVID-19 could negatively impact capital expenditures and overall economic activity in the impacted regions or depending on the severity, globally, which could impact the demand for the Company’s products and services. It is unknown whether and how the Company may be impacted if the COVID-19 pandemic persists for an extended period of time or if there are increases in its breadth or in its severity, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which the Company is subject. The COVID-19 pandemic poses a risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period. The Company may incur expenses or delays relating to such events outside of its control, which could have a material adverse impact on its business, operating results, financial condition and the trading price of its common stock.
Going Concern		Going Concern The Company has had negative cash flows from operations and operated at a net loss since inception. In the prior year our auditors included a paragraph in their opinion regarding the substantial doubt that existed of our ability to continue as a going concern. As noted in note 14 we completed our initial public offering subsequent to year end. We believe that the funds raised and notes that were converted from debt to equity now provides enough liquidity to alleviate the substantial doubt. There can be no assurance that we will not need additional funding in the future.
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of Bullfrog AI Holdings, Inc. and our wholly owned subsidiaries and have been prepared in conformity with United States generally accepted accounting principles (“GAAP”) for interim financial information. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated statements are unaudited and should be read in conjunction with the consolidated financial statements and related notes included in our 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 25, 2023. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with the audited annual consolidated financial statements included in the 10-K and, in the opinion of management, include all adjustments of a normal recurring nature necessary to fairly state our financial position, our results of operations, and cash flows. The results for the nine months ended September 30, 2023 are not necessarily indicative of the operating results expected for the year ending December 31, 2023 or any other future period. On February 13, 2023, we completed a 1-for-7 reverse split of our common stock.
Contract Services	Contract Services The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis. Once data analysis and the analysis report is complete, the Company delivers the analysis set to the customer and recognizes revenue at that point in time.
Significant Accounting Policies	Significant Accounting Policies There have been no new or material changes to the significant accounting policies discussed in the Company’s audited financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Convertible Debt	Schedule of Convertible Debt Note Date Purchase Price Principal Balance Original Issue Discount Accrued Interest Note Purchase Principal Original Issue Accrued Date Price Balance Discount Interest 4/28/2022 $ 250,000 $ 277,778 $ 27,778 $ 17,083 4/28/2022 $ 250,000 $ 277,778 $ 27,778 $ 17,083 4/28/2022 $ 250,000 $ 277,778 $ 27,778 $ 17,083 4/28/2022 $ 25,000 $ 27,778 $ 2,778 $ 1,708 4/28/2022 $ 28,000 $ 31,111 $ 3,111 $ 1,913 4/28/2022 $ 28,000 $ 31,111 $ 3,111 $ 1,913 4/28/2022 $ 35,000 $ 38,889 $ 3,889 $ 2,392 12/20/2021 $ 25,000 $ 27,778 $ 2,778 $ 2,301 4/13/2022 $ 100,000 $ 111,111 $ 11,111 $ 7,111 9/9/2022 $ 25,000 $ 27,778 $ 2,778 $ 1,088 Total $ 1,016,000 $ 1,128,889 $ 112,889 $ 69,675 * Notes sold by Company prior to the April 28, 2022 closing

Stockholder_s Equity (Tables)

Stockholder’s Equity (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Schedule of Stock Options Activity	The following table summarizes the stock option activity for the nine months ended September 30, 2023: Schedule of Stock Options Activity Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at December 31, 2022 69,217 $ 3.06 7.08 $ 117,669 Granted 438,500 $ 4.41 - $ - Exercised - $ - - $ - Forfeited / canceled - $ - - $ - Outstanding at September 30, 2023 507,717 $ 4.23 9.17 $ 102,441 Vested at September 30, 2023 215,623 $ 3.97 8.64 $ 52,644	The following tables summarizes the stock options (post reverse stock split) activity for the years ended December 31, 2022 and 2021: Schedule of Stock Options Activity Granted and outstanding, December 31, 2020 884,821 Granted during 2021 29,286 Exercised - Forfeited - Expired during 2021 (445,536 ) Granted and outstanding, December 31, 2021 468,571 Granted during 2022 - Exercised - Forfeited (399,354 ) Expired during 2022 - Granted and outstanding, December 31, 2022 69,217
Schedule of Vested and Outstanding Options		Schedule of Vested and Outstanding Options Options Intrinsic Value of Vested Options Weight Averaged exercise Price Vested and outstanding, December 31, 2020 104,795 12,706 3.36 Granted and vested during 2021 1,310 157 2.66 Exercised - - - Forfeited - - - Expired (66,524 ) (7,922 ) (3.36 ) Vested and outstanding, December 31, 2021 39,581 4,941 3.36 Granted and vested during 2022 16,661 2,010 2.73 Exercised - - - Forfeited - - - Expired - - - Vested and outstanding, December 31, 2022 56,242 6,951 3.15
Schedule of Black Scholes Option Pricing Model	The fair value of options granted in the nine months ended September 30, 2023 were estimated using the Black-Scholes option pricing model based on the assumptions in the table below: Schedule of Black Scholes Option Pricing Model 2023 Expected dividend yield 0% Expected volatility 87 92% Risk-free interest rate 3.4 4.1 Expected life (in years) 5.0 6.0	Schedule of Black Scholes Option Pricing Model December 31, 2022 December 31, 2021 Fair Value of Common Stock on measurement date $ 4.76 $ 0.308 Risk free interest rate From 0.79 3.01 % From 1.26 1.33 % Volatility 89 % 93 % Dividend Yield 0 % 0 % Expected Term 4 10 10
Schedule of Stock Warrant Activity		The following tables summarize the warrant activity (post reverse stock split) for the year ended December 31, 2022 and 2021, Schedule of Stock Warrant Activity Warrants Granted and outstanding, December 31, 2020 495,714 Granted during 2021 431,659 Exercised - Forfeited - Expired during 2021 - Granted and outstanding, December 31, 2021 927,373 Granted during 2022 123,660 Exercised - Forfeited (298,088 ) Expired during 2022 - Granted and outstanding, December 31, 2022 752,945
Schedule of Vested And Outstanding Warrants		Schedule of Vested And Outstanding Warrants Warrants Intrinsic Value of Warrants Weight Averaged exercise Price Vested and outstanding, December 31, 2020 479,940 127,480 0.98 Granted and Vested 2021 137,552 22,208 3.15 Exercised - - - Forfeited - - - Expired - - - Vested and outstanding, December 31, 2021 617,492 149,688 2.80 Granted and Vested 2022 174,105 337,263 3.15 Exercised - - - Forfeited (94,665 ) (12,980 ) - Expired - - - Vested and outstanding, December 31, 2022 696,932 473,971 1.96
Schedule of Outstanding Warrants	The following table provides details over the Company’s outstanding warrants as of September 30, 2023: Schedule of Outstanding Warrants Exercise Price Expiration Number of Warrants $ 0.0007 2030 274,286 $ 2.10 2.66 2026 2032 460,445 $ 3.36 4.27 2028 2029 115,277 $ 6.51 7.80 2026 2032 1,484,929 $ 8.125 2027 2028 1,461,227 3,796,164	The following table provides details over the Company’s outstanding warrants as of September 30, 2023: Schedule of Outstanding Warrants Exercise Price Expiration Number of Warrants $ 0.0007 2030 274,286 $ 2.10 2.66 2026 2032 460,445 $ 3.36 4.27 2028 2029 115,277 $ 6.51 7.80 2026 2032 1,484,929 $ 8.125 2027 2028 1,461,227 3,796,164
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Schedule of Black Scholes Option Pricing Model		Schedule of Black Scholes Option Pricing Model December 31, 2022 December 31, 2021 Fair Value of Common Stock on measurement date $ 4.76 $ 0.308 Risk free interest rate From 1.86 1.97 % From 0.78 1.63 % Volatility 89 % 93 % Dividend Yield 0 % 0 % Expected Term 10 5 10

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Deferred Taxes	The Company’s deferred taxes as of December 31, 2022 and 2021 consist of the following: Schedule of Deferred Taxes 2022 2021 Non-Current deferred tax asset: Net operating loss carryforwards $ 924,000 $ 339,000 Valuation allowance (924,000 ) (339,000 ) Net non-current deferred tax asset $ — $ —

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Feb. 13, 2023	Feb. 28, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
First service revenue			$ 65,000		$ 65,000		$ 10,000
Unearned revenue							32,000	10,000
Cash balances							57,670	10,014
Allowance for doubtful accounts							0	0
Cost of services			$ 5,200		$ 5,200		$ 800
Royalty percent							8%
Number of options							753,174	927,373
Reverse stock split							1-for-7 reverse stock split
IPO [Member]
Reverse stock split	completed a 1-for-7 reverse split of our common stock.
Common Stock [Member]
Number of options					507,717	484,525	56,242	486,571
Common Stock [Member] | IPO [Member]
Reverse stock split		completed a 1-for-7 reverse split of our common stock.

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Payment to acquire equiment		$ 8,744	$ 8,744
Accumulated depreciation			1,045
Property and equipment net	6,406		7,699
Depreciation	$ 1,293	$ 604	$ 1,045

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Details Narrative) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	$ 1,526,981	$ 422,817

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Feb. 28, 2023	Sep. 30, 2023	Sep. 30, 2022	Jan. 31, 2023	May 05, 2020
Short-Term Debt [Line Items]
Repayments in installments		$ 319,950
Short-Term Debt [Member]
Short-Term Debt [Line Items]
Notes payable	$ 697,534			$ 100,000
Accrued interest	6.50%			9%
Original issuance discount rate				20%
Repayments in installments	$ 71,485
Outstanding balance		213,290
Prepaid expenses		$ 307,735
SBA PPP Loan [Member]
Short-Term Debt [Line Items]
Notes payable					$ 9,917
Accrued interest					1%

Notes Payable Related Party (De

Notes Payable Related Party (Details Narrative) - USD ($)				1 Months Ended
	Dec. 13, 2021	Nov. 19, 2021	Jun. 15, 2021	Dec. 31, 2021	Sep. 30, 2023	Dec. 31, 2022
Notes Payable Related Party
Short term loan	$ 10,000	$ 5,000	$ 34,000		$ 213,290
Accruing interest rate	5%	5%	5%	5%
Interest rate	1%	1%	1%	1%
Short term loan				$ 49,000

Schedule of Convertible Debt (D

Schedule of Convertible Debt (Details) - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Original Issue Discount		$ 0	$ 12,962
Convertible Debt One [Member] | Wallach Beth [Member]
Short-Term Debt [Line Items]
Purchase Price		250,000
Principal Balance		277,778
Original Issue Discount		27,778
Accrued Interest		$ 17,083
Note Date		Apr. 28, 2022
Convertible Debt Two [Member] | Wallach Beth [Member]
Short-Term Debt [Line Items]
Purchase Price		$ 250,000
Principal Balance		277,778
Original Issue Discount		27,778
Accrued Interest		$ 17,083
Note Date		Apr. 28, 2022
Convertible Debt Three [Member] | Wallach Beth [Member]
Short-Term Debt [Line Items]
Purchase Price		$ 250,000
Principal Balance		277,778
Original Issue Discount		27,778
Accrued Interest		$ 17,083
Note Date		Apr. 28, 2022
Convertible Debt Four [Member] | Wallach Beth [Member]
Short-Term Debt [Line Items]
Purchase Price		$ 25,000
Principal Balance		27,778
Original Issue Discount		2,778
Accrued Interest		$ 1,708
Note Date		Apr. 28, 2022
Convertible Debt Five [Member] | Wallach Beth [Member]
Short-Term Debt [Line Items]
Purchase Price		$ 28,000
Principal Balance		31,111
Original Issue Discount		3,111
Accrued Interest		$ 1,913
Note Date		Apr. 28, 2022
Convertible Debt Six [Member] | Wallach Beth [Member]
Short-Term Debt [Line Items]
Purchase Price		$ 28,000
Principal Balance		31,111
Original Issue Discount		3,111
Accrued Interest		$ 1,913
Note Date		Apr. 28, 2022
Convertible Debt Seven [Member] | Wallach Beth [Member]
Short-Term Debt [Line Items]
Purchase Price		$ 35,000
Principal Balance		38,889
Original Issue Discount		3,889
Accrued Interest		$ 2,392
Note Date		Apr. 28, 2022
Convertible Debt Eight [Member] | Wallach Beth [Member]
Short-Term Debt [Line Items]
Purchase Price		$ 25,000
Principal Balance		27,778
Original Issue Discount		2,778
Accrued Interest		$ 2,301
Note Date	[1]	Dec. 20, 2021
Convertible Debt Nine [Member] | Wallach Beth [Member]
Short-Term Debt [Line Items]
Purchase Price		$ 100,000
Principal Balance		111,111
Original Issue Discount		11,111
Accrued Interest		$ 7,111
Note Date	[1]	Apr. 13, 2022
Convertible Debt Ten [Member] | Wallach Beth [Member]
Short-Term Debt [Line Items]
Purchase Price		$ 25,000
Principal Balance		27,778
Original Issue Discount		2,778
Accrued Interest		$ 1,088
Note Date		Sep. 09, 2022
Convertible Debt [Member] | Wallach Beth [Member]
Short-Term Debt [Line Items]
Purchase Price		$ 1,016,000
Principal Balance		1,128,889
Original Issue Discount		112,889
Accrued Interest		$ 69,675
[1]Notes sold by Company prior to the April 28, 2022 closing

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)								1 Months Ended			3 Months Ended	9 Months Ended		12 Months Ended
	Feb. 28, 2023	Apr. 28, 2022	Dec. 20, 2021	Aug. 31, 2021	Aug. 19, 2021	Aug. 09, 2021	Mar. 27, 2020	Sep. 30, 2022	Apr. 30, 2022	Aug. 31, 2021	Dec. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	May 31, 2022
Short-Term Debt [Line Items]
Conversion of stock, value													$ 226,138	$ 226,138
Conversion of stock, shares														205,984
Unamortized debt discount											$ 0			$ 0	12,962
Amortization of debt discount												20,000	174,998	214,429	12,665
Proceeds from notes payable												$ 100,000
Convertible Bridge Notes And Warrants [Member]
Short-Term Debt [Line Items]
Conversion of stock, shares	269,513
Debt description								The purchasers will also be issued a warrant for each share of common stock issued upon conversion of the Note at a price equal to 110% of the IPO price or, if the Company fails to complete the IPO before October 22, 2022, 90% of the IPO price.
Convertible Loan Agreement [Member]
Short-Term Debt [Line Items]
Principal balance				$ 195,000		$ 195,000				$ 195,000
Interest rate				9%	9%	9%				9%
Maturity date					Feb. 19, 2022	Feb. 09, 2022				Feb. 09, 2022
Conversion of stock, shares	21,747		6,939
Principal balance											$ 123,000			$ 123,000	72,000
Original issuance discount rate				5%	5%	5%
Number of warrants	99,000		355,114		99,900	195,000					195,000			195,000		225,000
Exercise price	$ 1				$ 1	$ 1					$ 1			$ 1		$ 2.50
Warrants term					5 years	5 years					5 years			5 years
Unamortized debt discount											$ 6,150			$ 6,150
Accrued interest											35,078			35,078
Proceeds from notes payable														123,000	$ 72,000
Conversion discount rate										20%
Convertible Loan Agreement [Member] | August 2021 [Member]
Short-Term Debt [Line Items]
Principal balance											195,000			195,000
New Agreement [Member]
Short-Term Debt [Line Items]
Principal balance											195,000			195,000
Number of warrants																225,000
Exercise price																$ 2.50
Unamortized debt discount											0			0
Accrued interest											35,078			35,078
Amortization of debt discount														8,393
Warrant expenses														$ 64,978
Loan Agreement [Member]
Short-Term Debt [Line Items]
Interest rate			6%
Maturity date			Dec. 19, 2022
Principal balance			$ 25,000
Original issuance discount rate			10%											10%
Accrued interest											$ 2,301			$ 2,301
Prncipal balance increase														2,778
Proceeds from notes payable			$ 25,000						$ 1,000,000
Maryland Technology Development Corporation [Member] | Convertible Loan Agreement [Member]
Short-Term Debt [Line Items]
Principal balance							$ 200,000
Interest rate							6%
Maturity date							Sep. 27, 2021
Conversion of stock, value														$ 226,138
Conversion of stock, shares														205,984
Fully diluted equity							$ 5,000,000
Wallach Beth [Member]
Short-Term Debt [Line Items]
Fees expense		$ 91,560
Wallach Beth [Member] | Convertible Bridge Notes And Warrants [Member]
Short-Term Debt [Line Items]
Principal balance								$ 27,779					$ 27,779
Maturity date								Oct. 31, 2022
Original issuance discount rate		10%						10%
Exercise price								$ 4.27			$ 4.27		$ 4.27	$ 4.27
Proceeds from notes payable		$ 775,000						$ 25,000
Fees expense		91,000
Sale of stock value		$ 100,000
Conversion discount rate								20%
Debt description								The agreement provided for the warrants to be exercisable for a period of five years from issuance at an exercise price equal to 110% of the IPO price or, if the Company failed to complete the IPO before October 22, 2022, 90% of the IPO price.
Maturity date extended								Dec. 31, 2022
Conversion value								$ 25,000,000			$ 25,000,000
Conversion price											$ 4.27			$ 4.27

Convertible Notes Payable Rel_2

Convertible Notes Payable Related Party (Details Narrative) - USD ($)						1 Months Ended	12 Months Ended
	Feb. 28, 2023	Dec. 20, 2021	Aug. 31, 2021	Aug. 19, 2021	Aug. 09, 2021	Aug. 31, 2021	Dec. 31, 2022	May 31, 2022	Dec. 31, 2021	Jul. 08, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Conversion of stock, shares							205,984
Simple Agreement for Future Equity [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Convertible notes payable related party							$ 150,000		$ 150,000	$ 150,000
Interest rate							6%		6%	0%
Conversion of stock, shares	32,967
Loss on the conversion	$ 63,626
Simple Agreement for Future Equity [Member] | Related Party [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Notes payable										$ 150,000
Convertible Loan Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Convertible notes payable related party				$ 99,900
Interest rate			9%	9%	9%	9%
Original issuance discount rate			5%	5%	5%
Number of warrant shares	99,000	355,114		99,900	195,000		195,000	225,000
Warrant exercise price per share	$ 1			$ 1	$ 1		$ 1	$ 2.50
Warrants term				5 years	5 years		5 years
Maturity date				Feb. 19, 2022	Feb. 09, 2022	Feb. 09, 2022
Principal amount							$ 123,000		$ 72,000
Accrued interest							35,078
Conversion of stock, shares	21,747	6,939
Loss on the conversion	$ 29,333
New Loan Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of warrant shares								115,185
Warrant exercise price per share								$ 2.50
Principal amount							99,900
Repayments of debt							4,950
Accrued interest							$ 12,463.53

Related Party (Details Narrativ

Related Party (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended
	Feb. 28, 2023	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Accrued salaries							$ 566,916	$ 285,666
Accrued consulting fees							90,000
Number of shares issued for services	7,692		436,533					29,286
Stock-based compensation related to outstanding stock options		$ 936,000			$ 936,000		1,803
Original life					8 years 7 months 20 days
Stock-based compensation					$ 511,177	$ 290,876	$ 340,152	$ 98,951
Share-Based Payment Arrangement, Option [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of shares issued for services								29,286
Original life								10 years
Stock-based compensation		$ 430		$ 450	$ 1,290	$ 1,350
Chief Financial Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of shares issued								57,143
Number of shares issued for services					75,000

Schedule of Stock Options Activ

Schedule of Stock Options Activity (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Number of Shares, Outstanding at Beginning	69,217	468,571	884,821
Number of Shares, Granted	438,500		29,286
Number of Shares, Exercised
Forfeited		(399,354)
Expired			(445,536)
Number of Shares, Outstanding at Ending	507,717	69,217	468,571
Weighted-Average Exercise Price, Outstanding at Beginning	$ 3.06
Weighted-Average Remaining Contractual Term (Years), Outstanding	9 years 2 months 1 day	7 years 29 days
Aggregate Intrinsic Value, Outstanding at Beginning	$ 117,669
Weighted-Average Exercise Price, Granted	$ 4.41
Aggregate Intrinsic Value, Granted
Weighted-Average Exercise Price, Exercised
Aggregate Intrinsic Value, Exercised
Number of Shares, Forfeited / canceled		399,354
Weighted-Average Exercise Price, Forfeited / canceled
Aggregate Intrinsic Value, Forfeited / canceled
Weighted-Average Exercise Price, Outstanding at Ending	$ 4.23	$ 3.06
Aggregate Intrinsic Value, Outstanding at Ending	$ 102,441	$ 117,669
Number of Shares, Vested at Ending	215,623	56,242	39,581	104,795
Weighted-Average Exercise Price, Vested at Ending	$ 3.97	$ 3.15	$ 3.36	$ 3.36
Weighted-Average Remaining Contractual Term (Years), Vested at Ending	8 years 7 months 20 days
Aggregate Intrinsic Value, Vested at Ending	$ 52,644	$ 6,951	$ 4,941	$ 12,706

Schedule of Vested and Outstand

Schedule of Vested and Outstanding Options (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Beginning value, Options	39,581	104,795
Beginning value, Intrinsic Value of Vested Options	$ 4,941	$ 12,706
Weight Averaged exercise Price, beginning value	$ 3.36	$ 3.36
Options Granted	16,661	1,310
Intrinsic Value of Vested Options, Granted	$ 2,010	$ 157
Weight Averaged exercise Price, Granted	$ 2.73	$ 2.66
Options Exercised
Intrinsic Value of Vested Options, Exercised
Weight Averaged exercise Price, Exercised
Options Forfeited
Intrinsic Value of Vested Options, Forfeited
Weight Averaged exercise Price, Forfeited
Options Expired		(66,524)
Intrinsic Value of Vested Options, Expired		$ (7,922)
Weight Averaged exercise Price, Expired		$ (3.36)
Ending value, Options	56,242	39,581
Intrinsic Value of Vested Options, Intrinsic value	$ 6,951	$ 4,941
Weight Averaged exercise Price, Ending balance value	$ 3.15	$ 3.36

Schedule of Black Scholes Optio

Schedule of Black Scholes Option Pricing Model (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Fair Value of Common Stock on measurement date		$ 4.76	$ 0.308
Risk-free interest rate, minimum	3.40%	0.79%	1.26%
Risk-free interest rate, maximum	4.10%	3.01%	1.33%
Volatility		89%	93%
Expected dividend yield	0%	0%	0%
Expected life (in years)			10 years
Expected volatility, minimum	87%
Expected volatility, maximum	92%
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Fair Value of Common Stock on measurement date		$ 4.76	$ 0.308
Risk-free interest rate, minimum		1.86%	0.78%
Risk-free interest rate, maximum		1.97%	1.63%
Volatility		89%	93%
Expected dividend yield		0%	0%
Expected life (in years)			10 years
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected life (in years)	5 years	4 years
Minimum [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected life (in years)			5 years
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected life (in years)	6 years	10 years
Maximum [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected life (in years)			10 years

Schedule of Stock Warrant Activ

Schedule of Stock Warrant Activity (Details) - Warrant [Member] - shares	1 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance			752,945	927,373	927,373	495,714
Granted			3,195,906	56,623	123,660	431,659
Exercised		436,533
Forfeited	(200,000)				(298,088)
Expired
Ending balance					752,945	927,373

Schedule of Vested And Outsta_2

Schedule of Vested And Outstanding Warrants (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning value, Intrinsic Value of Vested Options	$ 4,941	$ 12,706
Weight Averaged exercise Price, beginning value	$ 3.36	$ 3.36
Intrinsic Value of Vested Options, Intrinsic value	$ 6,951	$ 4,941
Weight Averaged exercise Price, Ending balance value	$ 3.15	$ 3.36
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	617,492	479,940
Beginning value, Intrinsic Value of Vested Options	$ 149,688	$ 127,480
Weight Averaged exercise Price, beginning value	$ 2.80	$ 0.98
Warrants Granted	174,105	137,552
Intrinsic Value of Vested Warrants, Granted	$ 337,263	$ 22,208
Weight Averaged exercise Price, Granted	$ 3.15	$ 3.15
Warrants, Exercised
Intrinsic Value of Vested Warrants, Exercised
Weight Averaged exercise Price, Exercised
Warrants Forfeited	(94,665)
Intrinsic Value of Vested Warrants, Forfeited	$ (12,980)
Weight Averaged exercise Price, Forfeited
Warrants, Expired
Intrinsic Value of Vested Warrants, Expired
Weight Averaged exercise Price, Expired
Ending balance value	696,932	617,492
Intrinsic Value of Vested Options, Intrinsic value	$ 473,971	$ 149,688
Weight Averaged exercise Price, Ending balance value	$ 1.96	$ 2.80

Schedule of Outstanding Warrant

Schedule of Outstanding Warrants (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Class of Warrant or Right [Line Items]
Number of Warrants | shares	3,796,164
Exercise Price [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.0007
Expiration Period	2030
Number of Warrants | shares	274,286
Exercise Price One [Member]
Class of Warrant or Right [Line Items]
Number of Warrants | shares	460,445
Exercise Price One [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 2.10
Expiration Period	2026
Exercise Price One [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 2.66
Expiration Period	2032
Exercise Price Two [Member]
Class of Warrant or Right [Line Items]
Number of Warrants | shares	115,277
Exercise Price Two [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 3.36
Expiration Period	2028
Exercise Price Two [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 4.27
Expiration Period	2029
Exercise Price Three [Member]
Class of Warrant or Right [Line Items]
Number of Warrants | shares	1,484,929
Exercise Price Three [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 6.51
Expiration Period	2026
Exercise Price Three [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 7.80
Expiration Period	2032
Exercise Price Four [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 8.125
Number of Warrants | shares	1,461,227
Exercise Price Four [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Expiration Period	2027
Exercise Price Four [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Expiration Period	2028

Stockholder_s Equity (Details N

Stockholder’s Equity (Details Narrative) - USD ($)					1 Months Ended				3 Months Ended						9 Months Ended		12 Months Ended
	Feb. 28, 2023	Feb. 13, 2023	Nov. 30, 2022	Oct. 05, 2022	Feb. 28, 2023	Nov. 30, 2022	Jun. 30, 2022	Jun. 30, 2020	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	May 31, 2022	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized									10,000,000						10,000,000		10,000,000
Preferred stock, par or stated value per share									$ 0.00001						$ 0.00001		$ 0.00001
Preferred stock, shares issued																		0
Number of common stock				10													10
Preferred stock value									$ 1						$ 1		$ 1
Stock split, description								BullFrog AI Holdings, Inc. acquired BullFrog AI, Inc. via a 1:1 share exchange. Immediately prior to the share exchange, each authorized common share of BullFrog AI, Inc. was split into 25 shares of common stock
Common stock, shares authorized									100,000,000						100,000,000		100,000,000	100,000,000
Common stock, par or stated value per share									$ 0.00001						$ 0.00001		$ 0.00001	$ 0.00001
Conversion of convertibe notes value											$ 1,535,615		$ 226,138				$ 226,138
Shares issued value										$ 1,494,658							$ 189,828
Common stock, shares outstanding									6,094,644						6,094,644		4,021,935	4,622,789
Reverse stock split																	1-for-7 reverse stock split
Number of options forfeitures																	399,354
Share based compensation granted															438,500			29,286
Original life															9 years 2 months 1 day		7 years 29 days
Share-based payment arrangement, expensed and capitalized, amount															$ 511,177	$ 290,876	$ 340,152	$ 98,951
Option vested shares																	16,661	1,310
Option vested expired shares																		(66,524)
Weighted average remaining contractual term															8 years 7 months 20 days
Warrant shares																	92,859	92,859
Warrants shares, outstanding									3,796,164						3,796,164
Conversion of stock, shares																	205,984
Conversion of convertible notes value																226,138	$ 226,138
Shares, issued for services					7,692					436,533								29,286
Value, issued for services					$ 50,000						$ 50,000
Proceeds from exercise of warrant										$ 1,494,658					$ 1,494,658
Number of options																	753,174	927,373
Weighted-average grant-date fair value of options granted															$ 3.20
Compensation expense related to stock options									$ 116,410			$ 51,536			$ 475,465	$ 290,876
Unrecognized compensation expense									$ 936,000						$ 936,000		$ 1,803
Weighted-average period															2 years 1 month 6 days
Weighted average period term															4 months 24 days
Tradeable Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price	$ 7.80				$ 7.80
Sale of stock, description					Each Unit consisted of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $7.80 per share
Non-Tradeable Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price	8.125				$ 8.125
Sale of stock, description					non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $8.125.
IPO [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock split		completed a 1-for-7 reverse split of our common stock.
Warrant shares			276,289			276,289
Conversion of stock, shares			276,289		331,166
Conversion of convertible notes value			$ 25,000,000
Additional shares issued					1,297,318
Issue price per share	$ 6.50				$ 6.50
Gross proceeds					$ 8,400,000
Equity Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of options forfeitures														399,354
Share based compensation granted																		29,286
Original life																		10 years
Award period																		48 months
Warrants shares vested																		1,310
Share-based payment arrangement, expensed and capitalized, amount																	2,010	$ 157
Share-based payment arrangement, expensed and capitalized, amount																	$ 16,601
Option vested shares																	16,661	1,310
Option vested expired shares																		66,524
Weighted average remaining contractual term																	7 years 29 days	7 years 4 months 17 days
Fair value of warrants																	$ 6,951	$ 4,941
Series A Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized									5,500,000						5,500,000		5,500,000
Preferred stock, par or stated value per share									$ 0.00001						$ 0.00001		$ 0.00001
Preferred stock, shares issued									73,449						73,449		73,449
Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized																	5,500,000	5,500,000
Preferred stock, par or stated value per share																	$ 0.00001	$ 0.00001
Preferred stock, shares issued																	73,449	0
Preferred stock value				$ 315,000
Note Holder [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Conversion of convertible securities, shares																	205,984
Exchange Agreement [Member] | Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Conversion of convertible securities, shares																	734,429
Exchange Agreement [Member] | Investor [Member] | Series A Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Conversion of convertible securities, shares				73,449
Prior Agreements And New Agreements [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares cancelled																	112,225
Twenty Twenty Two Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Award period						10 years
Award authorized under the plan			900,000			900,000			461,500						461,500
Increased payment award, percentage						15%
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Conversion of convertible securities, shares											331,166		205,984				205,984
Conversion of convertibe notes value											$ 3		$ 2				$ 2
Shares cancelled																	112,225
Number of shares issued											1,297,318
Shares issued value										$ 4
Shares cancelled													112,225
Shares, issued for services											7,692
Value, issued for services											$ 1
Number of options															507,717	484,525	56,242	486,571
Common Stock [Member] | IPO [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock split					completed a 1-for-7 reverse split of our common stock.
Common Stock [Member] | Exchange Agreement [Member] | Investor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Conversion of convertible securities, shares				734,492
Common Stock [Member] | License Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																	38,879
Shares issued value																	$ 189,828
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants shares vested															22,939		174,105	0
Weighted average remaining contractual term																	7 years 1 month 17 days	7 years 8 months 23 days
Fair value of warrants																	$ 324,283	$ 149,688
Share based compensation granted															3,195,906	56,623	123,660	431,659
Contractual life and vesting period, description															The warrants have an original life of ten years and vest immediately and over 12 months.		The warrants have an original life of four to ten years and vest immediately and over 12 months.	The warrants have an original life of ten years and vest at different rates over as much as 36 months.
Intrinsic value															$ 35,712		$ 337,269
Warrant shares																	51,941	138,929
Warrants reclassified with intrinsic value																	$ 11,097
Warrant shares, forfeited																	42,057		99,000
Fair value of warrants							$ 11,097						$ 11,097					$ 28,683
Warrant shares forfeiture							200,000										298,088
Warrant shares							50,735						50,735
Exercise price																			$ 1
Warrants shares, outstanding																	752,945	927,516
Vested shares																	696,932	617,492		479,940
Intrinsic value																	$ 337,263	$ 22,208
Warrant exercised										436,533
Number of options															3,796,164	5,270,617
Warrant shares, forfeited																	$ 1,883
Compensation expense									$ 5,050			$ 51,086			$ 35,712	$ 289,317
Warrant [Member] | IPO [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Additional shares issued	276,452
Issue price per share	$ 4.27				$ 4.27
Weighted average period term	5 years
Warrant [Member] | Underwriters [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Additional shares issued	18,000
Issue price per share	$ 8.125				8.125
Weighted average period term	4 years
Warrant [Member] | Advisors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share based compensation granted																		200,000
Contractual life and vesting period, description																		The warrants have an original life of five years and vest 30 days before the intended IPO
Fair value of warrants																		$ 12,462
Warrant [Member] | Convertible Bridge Debt Agreements [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant shares																		92,859
Fair value of warrants																		$ 12,980
Warrants and rights outstanding term																		5 years
Warrant [Member] | New Agreements [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant shares																			115,185
Fair value of warrants																			$ 15,412
Exercise price																			$ 2.50
Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant shares, forfeited																			195,000
Warrant One [Member] | New Agreements [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant shares																			225,000
Fair value of warrants																			$ 64,978
Exercise price																			$ 2.50
Tradable Warrant [Member] | IPO [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Additional shares issued	1,297,318
Issue price per share	$ 7.80				7.80
Weighted average period term	5 years
Tradable Warrant [Member] | Over-Allotment Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Additional shares issued	153,409
Issue price per share	$ 7.80				7.80
Weighted average period term	5 years
Non Tradable Warrant [Member] | IPO [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Additional shares issued	1,297,318
Issue price per share	$ 8.125				8.125
Weighted average period term	5 years
Non Tradable Warrant [Member] | Over-Allotment Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Additional shares issued	153,409
Issue price per share	$ 8.125				$ 8.125
Weighted average period term	5 years
Unvested Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Unrecognized compensation expense															6,556

Schedule of Deferred Taxes (Det

Schedule of Deferred Taxes (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 924,000	$ 339,000
Valuation allowance	(924,000)	(339,000)
Net non-current deferred tax asset

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	Dec. 31, 2022 USD ($)
Income Tax Disclosure [Abstract]
Operating loss carry forward	$ 4,399,055

Material Agreements (Details Na

Material Agreements (Details Narrative) - USD ($)

1 Months Ended

May 31, 2023

Feb. 28, 2023

Oct. 13, 2022

Jul. 08, 2022

Feb. 22, 2022

Feb. 07, 2018

Oct. 31, 2021

Sep. 30, 2023

Dec. 31, 2022

Jan. 14, 2022

Dec. 31, 2021

Dec. 13, 2021

Nov. 19, 2021

Jun. 15, 2021

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Accrued royalty expenses

$ 0

$ 0

Fianance raised

213,290

$ 10,000

$ 5,000

$ 34,000

2023 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

$ 60,000

JHU - APL Technology License Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Warrant percent

5%

Royalty percent

8%

Percentage of sublicense

50%

Maintenance fee

$ 1,500

$ 1,500

JHU - APL Technology License Agreement [Member] | 2022 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

20,000

JHU - APL Technology License Agreement [Member] | 2023 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

80,000

JHU - APL Technology License Agreement [Member] | 2024 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

$ 300,000

New License Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

$ 275,000

Common stock issued

279,159

Accrued royalty expenses

30,000

New License Agreement [Member] | Maximum [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Percentage of sublicense

50%

New License Agreement [Member] | Minimum [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Sublicense fee based on revenue

25%

New License Agreement [Member] | Internally Development Drug Projects [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty percent

3%

New License Agreement [Member] | Other Parties [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty percent

8%

New License Agreement [Member] | 2022 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

60,000

$ 30,000

New License Agreement [Member] | 2023 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

75,000

80,000

Accrued royalty expenses

45,000

New License Agreement [Member] | 2024 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

$ 300,000

New License Agreement [Member] | 2025 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

75,000

New License Agreement [Member] | 2026 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

75,000

New License Agreement [Member] | 2027 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

$ 50,000

George Washington University - Beta2-spectrin siRNA License Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty percent

3%

Licence initiation fee

$ 20,000

Johns Hopkins University - Mebendazole License Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty percent

3.50%

Accrued royalty expenses

7,500

242,671

Upfront licence fee

$ 250,000

Annual minimum royalty payment

250,000

License fee initial payment

$ 200,000

50,000

Fianance raised

10,000,000

Johns Hopkins University - Mebendazole License Agreement [Member] | 2023 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

5,000

Johns Hopkins University - Mebendazole License Agreement [Member] | 2024 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

10,000

Johns Hopkins University - Mebendazole License Agreement [Member] | 2025 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

20,000

Johns Hopkins University - Mebendazole License Agreement [Member] | 2026 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

30,000

Johns Hopkins University - Mebendazole License Agreement [Member] | 2027 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

$ 50,000

Johns Hopkins University - Prodrug License Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty percent

4%

Upfront licence fee

$ 100,000

Annual minimum royalty payment

150,000

Johns Hopkins University - Prodrug License Agreement [Member] | 2027 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

5,000

Johns Hopkins University - Prodrug License Agreement [Member] | 2028 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

10,000

Johns Hopkins University - Prodrug License Agreement [Member] | 2029 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

20,000

Johns Hopkins University - Prodrug License Agreement [Member] | 2030 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

30,000

Johns Hopkins University - Prodrug License Agreement [Member] | 2031 [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Royalty payments

$ 50,000

License Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Accrued expense

$ 0

$ 133,238

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)					1 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
	Apr. 13, 2023	Feb. 14, 2023	Feb. 13, 2023	Nov. 30, 2022	Feb. 28, 2023	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Reverse stock split									1-for-7 reverse stock split
Converted common shares									205,984
Warrants exercised									92,859	92,859
Conversion of convertible note payable								$ 226,138	$ 226,138
Gross proceeds						$ 1,494,658	$ 1,494,658
Tradeable Warrants [Member]
Subsequent Event [Line Items]
Sale of stock, description					Each Unit consisted of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $7.80 per share
Exercise price					$ 7.80
Non-Tradeable Warrants [Member]
Subsequent Event [Line Items]
Sale of stock, description					non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $8.125.
Exercise price					$ 8.125
IPO [Member]
Subsequent Event [Line Items]
Additional shares issued					1,297,318
Issue price per share					$ 6.50
Gross proceeds					$ 8,400,000
Reverse stock split			completed a 1-for-7 reverse split of our common stock.
Converted common shares				276,289	331,166
Warrants exercised				276,289
Conversion of convertible note payable				$ 25,000,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Warrants exercised	436,533
Gross proceeds	$ 1,495,000
Subsequent Event [Member] | Tradeable Warrants [Member]
Subsequent Event [Line Items]
Sale of stock, description		Each Unit consists of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $7.80 per share
Exercise price		$ 7.80
Subsequent Event [Member] | Non-Tradeable Warrants [Member]
Subsequent Event [Line Items]
Sale of stock, description		one non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $8.125
Exercise price		$ 8.125
Subsequent Event [Member] | IPO [Member]
Subsequent Event [Line Items]
Additional shares issued		1,297,318
Issue price per share		$ 6.50
Gross proceeds		$ 8,400,000
Reverse stock split		the Company common shares were subject to a 1-7 reverse stock split - 1 share of new common for 7 shares then outstanding common stock
Converted common shares		55,787